

Approved



Nigeria

Country Operational Plan

FY 2018



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
State		103,094		103,094	654,000	757,094
USAID		131,413,470	25,000,000	156,413,470	39,373,339	195,786,809
DOD		6,793,480		6,793,480	2,704,837	9,498,317
HHS/CDC	1,962,500	80,217,508	0	82,180,008	0	82,180,008
Total	1,962,500	218,527,552	25,000,000	245,490,052	42,732,176	288,222,228

Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency						Total
	State	DOD	HHS/CDC	State/AF	State/SGAC	USAID	
CIRC		0	0	0		0	0
HBHC		310,801	3,885,264	0		1,946,445	6,142,510
HKID		0	19,528,310	0		11,838,289	31,366,599
HLAB		277,495	2,086,832	0		291,844	2,656,171
HMBL		0	69,630	0		0	69,630
HMIN		0	69,630	0		0	69,630
HTXD		95,075	0	0		84,802,908	84,897,983
HTXS		1,450,483	18,015,129	0		25,806,044	45,271,656
HVAB		0	69,630	0		0	69,630
HVCT		423,998	4,865,435	0		4,934,853	10,224,286
HVMS	103,094	2,737,191	8,989,242			10,027,492	21,857,019
HVOP		160,853	3,850,672	0		336,100	4,347,625
HVSI		547,452	14,239,930	0	0	494,857	15,282,239
HVTB		140,302	801,122	0		1,869,448	2,810,872

Approved



IDUP		0	0	0		0	0
MTCT		404,843	3,308,626	0		5,876,550	9,590,019
OHSS		39,640	112,197	0		1,607,306	1,759,143
PDCS		110,206	1,479,019	0		3,982,439	5,571,664
PDTX		95,141	809,340	0		2,598,895	3,503,376
	103,094	6,793,480	82,180,008	0	0	156,413,470	245,490,052



Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount
HBHC	5,863,650
HKID	30,987,532
HVTB	2,408,273
PDCS	5,368,380
Total Technical Area Planned Funding:	44,627,835

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount
HLAB	1,779,810
HVSI	13,621,971
OHSS	1,149,004
Total Technical Area Planned Funding:	16,550,785

Technical Area: Prevention

Budget Code	Budget Code Planned Amount
CIRC	0
HMBL	0
HMIN	0
HVAB	0
HVCT	9,899,111
HVOP	4,159,894
IDUP	0
MTCT	9,213,360
Total Technical Area Planned Funding:	23,272,365

Approved



Technical Area: Treatment

Budget Code	Budget Code Planned Amount
HTXD	84,738,706
HTXS	44,719,123
PDTX	3,230,311
Total Technical Area Planned Funding:	132,688,140

Technical Area Summary Indicators and Targets

Indicator Number	Label	2019
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	95 %
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,521,926
	Number of new ANC and L&D clients	1,605,453
	By Age (Denominator): 10-14	3,087
	By Age (Denominator): <15-19	56,211
	By Age (Denominator): 20-24	310,891
	By Age (Denominator): 50+	8,132
	By Number of known positives: 10-14	15
	By Number of known positives: 15-19	854
	By Number of known positives: 20-24	4,746
	By Number of known positives: 50+	72
	By Number of new positives: 10-14	1
	By Number of new positives: 15-19	427
	By Number of new positives: 20-24	2,643
	By Number of new positives: 50+	25
	By Number of new negative: 10-14	2,861
	By Number of new negative: 15-19	52,016
	By Number of new negative: 20-24	287,913

	By Number of new negative: 50+	7,516
	By Age (Numerator): 10-14	2,927
	By Age (Numerator): 15-19	53,403
	By Age (Numerator): 20-24	295,326
	By Age (Numerator): 50+	7,696
	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	610,771
	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	415,129
	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	166,109
	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	35,123
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 25-29, Female, Known at Entry Positive	9,362
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 25-29, Female, Newly Identified Negative	565,684
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 25-29, Female, Newly Identified Positive	5,144
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 30-34, Female, Known at Entry Positive	6,369
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 30-34, Female, Newly Identified Negative	384,486
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 30-34, Female, Newly Identified Positive	3,438
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 35-39, Female, Known at Entry Positive	2,484

	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	153,851
	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	1,302
	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	403
	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	32,538
	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	181
	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	580,254
	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	394,384
	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	157,812
	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	33,349
PMTCT_ART_DSD	PMTCT_ART_DSD Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	2 %
	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	36,186
	Number of pregnant women with known HIV status (includes women	1,521,926



	who were tested for HIV and received their results)	
	New on ART	13,908
	Already on ART at beginning of current pregnancy	22,278
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	283,295
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	72,332
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	205,030
	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key	5,933

	populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.	100 %
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	42,202
	Total number of registered new and relapsed TB cases, during the reporting period.	42,202
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,503
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	23,526
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,376
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	15,838

	reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,503
	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	23,526
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,376
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	15,838
HTS_SELF_DSD	HTS_SELF_N_DSD	3,960
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 10-14, Female, Directly-Assisted	4
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 10-14, Female, Unassisted	4
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 10-14, Male, Directly-Assisted	3
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 10-14, Male, Unassisted	3
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Female, Directly-Assisted	34
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Female, Unassisted	34



	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Male, Directly-Assisted	6
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Male, Unassisted	6
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Female, Directly-Assisted	204
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Female, Unassisted	204
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Male, Directly-Assisted	40
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Male, Unassisted	40
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Female, Directly-Assisted	239
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Female, Unassisted	239
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Male, Directly-Assisted	119
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Male, Unassisted	119
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Female, Directly-Assisted	238
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Female, Unassisted	238
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Male,	62

	Directly-Assisted	
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Male, Unassisted	62
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Female, Directly-Assisted	205
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Female, Unassisted	205
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Male, Directly-Assisted	83
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Male, Unassisted	83
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Female, Directly-Assisted	263
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Female, Unassisted	263
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Male, Directly-Assisted	151
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Male, Unassisted	151
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 50+, Female, Directly-Assisted	106
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 50+, Female, Unassisted	106
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 50+, Male, Directly-Assisted	86
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 50+, Male, Unassisted	86

	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	1,980
	HTS_SELF_N_DSD_HIVSelfTest Unassisted	1,980
	HTS_SELF_N_DSD_HIVSelfTestU ser Unassisted - Other	193
	HTS_SELF_N_DSD_HIVSelfTestU ser Unassisted - Self	395
	HTS_SELF_N_DSD_HIVSelfTestU ser Unassisted - Sex Partner	395
	HTS_SELF_N_DSD_KeyPop_HIV SelfTest FSW, Directly-Assisted	13
	HTS_SELF_N_DSD_KeyPop_HIV SelfTest FSW, Unassisted	13
	HTS_SELF_N_DSD_KeyPop_HIV SelfTest MSM, Directly-Assisted	31
	HTS_SELF_N_DSD_KeyPop_HIV SelfTest MSM, Unassisted	31
	HTS_SELF_N_DSD_KeyPop_HIV SelfTest PWID, Directly-Assisted	76
	HTS_SELF_N_DSD_KeyPop_HIV SelfTest PWID, Unassisted	76
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	5,265,681
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	3,273
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	59
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	3,444
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	44



	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	5,738
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	76
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	3,840
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	30
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	10,795
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	406
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	5,988
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	106
	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	5,971
	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	309
	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	6,112
	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	239
	Service Delivery Point (Facility) Inpatient: <1, Negative	186
	Service Delivery Point (Facility) Inpatient: <1, Positive	2
	Service Delivery Point (Facility) Inpatient: 1-9, Negative	12,810
	Service Delivery Point (Facility) Inpatient: 1-9, Positive	216
	Service Delivery Point (Community) Mobile Testing: 15-19, Female,	12,040



	Negative	
	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	423
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	7,095
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	256
	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	40,274
	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	3,491
	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	23,374
	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	1,556
	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	4,959
	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	321
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	4,616
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	154
	Service Delivery Point (Facility) Other PITC: 10-14, Female,	62,088



	Negative	
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	640
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	62,328
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	670
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	81,643
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	1,141
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	55,637
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	513
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	172,913
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	4,779
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	110,126
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	1,639
	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	51,186
	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	1,222
	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	39,943



	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	940
	Service Delivery Point (Facility)Other PITC: <1, Negative	208
	Service Delivery Point (Facility) Other PITC: <1, Positive	5
	Service Delivery Point (Facility) Other PITC: 1-9, Negative	107,688
	Service Delivery Point (Facility) Other PITC: 1-9, Positive	1,339
	Service Delivery Point (Facility) Pediatric : <5 Negative	49,314
	Service Delivery Point (Facility) Pediatric : <5 Positive	1,069
	Service Delivery Point (Facility) TB: 10-14, Female, Negative	1,601
	Service Delivery Point (Facility) TB: 10-14, Female, Positive	57
	Service Delivery Point (Facility) TB: 10-14, Male, Negative	1,634
	Service Delivery Point (Facility) TB: 10-14, Male, Positive	45
	Service Delivery Point (Facility) TB: 15-19, Female, Negative	1,460
	Service Delivery Point (Facility) TB: 15-19, Female, Positive	163
	Service Delivery Point (Facility) TB: 15-19, Male, Negative	1,902
	Service Delivery Point (Facility) TB: 15-19, Male, Positive	164
	Service Delivery Point (Facility) TB: 20-24, Female, Negative	1,821
	Service Delivery Point (Facility) TB: 20-24, Female, Positive	119



	Service Delivery Point (Facility) TB: 20-24, Male, Negative	2,053
	Service Delivery Point (Facility) TB: 20-24, Male, Positive	155
	Service Delivery Point (Facility) TB: 50+, Female, Negative	2,370
	Service Delivery Point (Facility) TB: 50+, Female, Positive	278
	Service Delivery Point (Facility) TB: 50+, Male, Negative	2,128
	Service Delivery Point (Facility) TB: 50+, Male, Positive	255
	Service Delivery Point (Facility) TB: <1, Negative	178
	Service Delivery Point (Facility) TB: 1-9, Negative	328
	Service Delivery Point (Facility) TB: 1-9, Positive	82
	Service Delivery Point (Facility) Index: 10-14, Female, Negative	652
	Service Delivery Point (Facility) Index: 10-14, Female, Positive	5
	Service Delivery Point (Facility) Index: 10-14, Male, Negative	599
	Service Delivery Point (Facility) Index: 10-14, Male, Positive	6
	Service Delivery Point (Facility) Index: 15-19, Female, Negative	1,868
	Service Delivery Point (Facility) Index: 15-19, Female, Positive	102
	Service Delivery Point (Facility) Index: 15-19, Male, Negative	1,293
	Service Delivery Point (Facility) Index: 15-19, Male, Positive	21



	Service Delivery Point (Facility) Index: 20-24, Female, Negative	2,609
	Service Delivery Point (Facility) Index: 20-24, Female, Positive	875
	Service Delivery Point (Facility) Index: 20-24, Male, Negative	3,364
	Service Delivery Point (Facility) Index: 20-24, Male, Positive	870
	Service Delivery Point (Facility) Index: 50+, Female, Negative	951
	Service Delivery Point (Facility) Index: 50+, Female, Positive	150
	Service Delivery Point (Facility) Index: 50+, Male, Negative	2,711
	Service Delivery Point (Facility) Index: 50+, Male, Positive	756
	Service Delivery Point (Facility) Index: 1-9, Negative	2,473
	Service Delivery Point (Facility) Index: 1-9, Positive	62
	By Key Population: FSW, Negative	123,504
	By Key Population: FSW, Positive	9,377
	By Key Population: MSM, Negative	32,674
	By Key Population: MSM, Positive	4,212
	By Key Population: PWID, Negative	20,472
	By Key Population: PWID, Positive	1,521
	By Key Population: TG, Negative	289
	By Key Population: TG, Positive	37
	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	32
	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	45

	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	62
	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	88
	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	79
	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	179
	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	202
	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	124
	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	6
	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	12
	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	13
	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	13
	Service Delivery Point (Facility) ANC: 10-14, Negative	493
	Service Delivery Point (Facility) ANC: 10-14, Positive	1
	Service Delivery Point (Facility) ANC: 15-19, Negative	52,598
	Service Delivery Point (Facility) ANC: 15-19, Positive	186
	Service Delivery Point (Facility) ANC: 1-9, Negative	4
	Service Delivery Point (Facility) ANC: 20-24, Negative	293,337
	Service Delivery Point (Facility)	3,483



	ANC: 20-24, Positive	
	Service Delivery Point (Facility) ANC: 50+, Negative	593
	Service Delivery Point (Facility) ANC: 50+, Positive	60
	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	51,789
	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	899
	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	48,014
	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	842
	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	99,272
	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	2,079
	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	57,315
	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	1,300
	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	190,237
	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	7,488
	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	109,460
	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	2,896
	Service Delivery Point (Facility) VCT: 50+, Female, Negative	75,221
	Service Delivery Point (Facility) VCT: 50+, Female, Positive	4,046
	Service Delivery Point (Facility)	70,075

	VCT: 50+, Male, Negative	
	Service Delivery Point (Facility) VCT: 50+, Male, Positive	2,681
	Service Delivery Point (Facility) VCT: <1, Negative	3
	Service Delivery Point (Facility) VCT: <1, Positive	2
	Service Delivery Point (Facility) VCT: 1-9, Negative	52,397
	Service Delivery Point (Facility) VCT: 1-9, Positive	1,124
	HTS_TST_N_DSD_EW_Age_Sex_ Result 10-14, Female, Negative	1,114
	HTS_TST_N_DSD_EW_Age_Sex_ Result 10-14, Female, Positive	44
	HTS_TST_N_DSD_EW_Age_Sex_ Result 10-14, Male, Negative	1,114
	HTS_TST_N_DSD_EW_Age_Sex_ Result 10-14, Male, Positive	44
	HTS_TST_N_DSD_EW_Age_Sex_ Result 15-19, Female, Negative	901
	HTS_TST_N_DSD_EW_Age_Sex_ Result 15-19, Male, Negative	476
	HTS_TST_N_DSD_EW_Age_Sex_ Result 1-9, Unknown Sex, Negative	3,348
	HTS_TST_N_DSD_EW_Age_Sex_ Result 1-9, Unknown Sex, Positive	10
	HTS_TST_N_DSD_EW_Age_Sex_ Result 20-24, Female, Negative	668
	HTS_TST_N_DSD_EW_Age_Sex_ Result 20-24, Female, Positive	97
	HTS_TST_N_DSD_EW_Age_Sex_ Result 20-24, Male, Negative	2,417
	HTS_TST_N_DSD_EW_Age_Sex_	909



	Result 25-29, Female, Negative	
	HTS_TST_N_DSD_EW_Age_Sex_ Result 25-29, Female, Positive	1
	HTS_TST_N_DSD_EW_Age_Sex_ Result 25-29, Male, Negative	2,497
	HTS_TST_N_DSD_EW_Age_Sex_ Result 30-34, Female, Negative	1,141
	HTS_TST_N_DSD_EW_Age_Sex_ Result 30-34, Female, Positive	81
	HTS_TST_N_DSD_EW_Age_Sex_ Result 30-34, Male, Negative	2,050
	HTS_TST_N_DSD_EW_Age_Sex_ Result 30-34, Male, Positive	51
	HTS_TST_N_DSD_EW_Age_Sex_ Result 35-39, Female, Negative	1,590
	HTS_TST_N_DSD_EW_Age_Sex_ Result 35-39, Female, Positive	313
	HTS_TST_N_DSD_EW_Age_Sex_ Result 35-39, Male, Negative	2,512
	HTS_TST_N_DSD_EW_Age_Sex_ Result 35-39, Male, Positive	138
	HTS_TST_N_DSD_EW_Age_Sex_ Result 40-49, Female, Negative	1,595
	HTS_TST_N_DSD_EW_Age_Sex_ Result 40-49, Female, Positive	164
	HTS_TST_N_DSD_EW_Age_Sex_ Result 40-49, Male, Negative	2,048
	HTS_TST_N_DSD_EW_Age_Sex_ Result 40-49, Male, Positive	83
	HTS_TST_N_DSD_EW_Age_Sex_ Result 50+, Female, Negative	1,353
	HTS_TST_N_DSD_EW_Age_Sex_ Result 50+, Female, Positive	107
	HTS_TST_N_DSD_EW_Age_Sex_	2,491

	Result 50+, Male, Negative	
	HTS_TST_N_DSD_EW_Age_Sex_ Result 50+, Male, Positive	47
	HTS_TST_N_DSD_Index_Age_Sex_ Result 25-29, Female, Negative	2,430
	HTS_TST_N_DSD_Index_Age_Sex_ Result 25-29, Female, Positive	1,769
	HTS_TST_N_DSD_Index_Age_Sex_ Result 25-29, Male, Negative	1,569
	HTS_TST_N_DSD_Index_Age_Sex_ Result 25-29, Male, Positive	1,296
	HTS_TST_N_DSD_Index_Age_Sex_ Result 30-34, Female, Negative	2,388
	HTS_TST_N_DSD_Index_Age_Sex_ Result 30-34, Female, Positive	1,080
	HTS_TST_N_DSD_Index_Age_Sex_ Result 30-34, Male, Negative	4,717
	HTS_TST_N_DSD_Index_Age_Sex_ Result 30-34, Male, Positive	464
	HTS_TST_N_DSD_Index_Age_Sex_ Result 35-39, Female, Negative	3,976
	HTS_TST_N_DSD_Index_Age_Sex_ Result 35-39, Female, Positive	1,749
	HTS_TST_N_DSD_Index_Age_Sex_ Result 35-39, Male, Negative	5,678
	HTS_TST_N_DSD_Index_Age_Sex_ Result 35-39, Male, Positive	1,338
	HTS_TST_N_DSD_Index_Age_Sex_ Result 40-49, Female, Negative	2,842
	HTS_TST_N_DSD_Index_Age_Sex_ Result 40-49, Female, Positive	1,080
	HTS_TST_N_DSD_Index_Age_Sex_ Result 40-49, Male, Negative	3,171
	HTS_TST_N_DSD_Index_Age_Sex_	898



	x_Result 40-49, Male, Positive	
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 25-29, Female, Negative	9,620
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 25-29, Female, Positive	572
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 25-29, Male, Negative	7,921
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 30-34, Female, Negative	7,305
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 30-34, Female, Positive	365
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 30-34, Male, Negative	4,986
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 30-34, Male, Positive	2
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 35-39, Female, Negative	6,714
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 35-39, Female, Positive	799
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 35-39, Male, Negative	5,469
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 35-39, Male, Positive	406
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Female, Negative	7,641
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Female, Positive	384
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Male, Negative	6,003
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Male, Positive	728
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Female, Negative	38,362



	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	5,713
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	23,895
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	2,263
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	13,616
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	1,772
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	9,396
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	665
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	7,382
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	955
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	3,468
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	297
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	7,243
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	172
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	3,716



	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	222
	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	1
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	106
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	65
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	323
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	62
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	35
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	27
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	105
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	20
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	15
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	17
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	49
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	19



	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	15
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	15
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	47
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	24
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	235,108
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	4,764
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	137,688
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	2,870
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	134,819
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	4,777
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	109,900
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	1,480
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	105,634
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	3,693

	Positive	
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	80,101
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	2,832
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	91,389
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	6,049
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	69,653
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	3,385
	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	574,549
	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	6,800
	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	380,778
	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	1,622
	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	145,138
	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	1,379
	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female,	32,582

	Negative	
	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	11
	HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Female, Negative	2
	HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Female, Positive	1
	HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Male, Negative	2
	HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Male, Positive	1
	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	316
	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive	11
	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	540
	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Positive	9
	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	349
	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	11
	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	256
	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	184
	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Positive	27
	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	337
	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Positive	17

	HTS_TST_N_DSD_STI_Age_Sex_ Result 40-49, Female, Negative	469
	HTS_TST_N_DSD_STI_Age_Sex_ Result 40-49, Female, Positive	46
	HTS_TST_N_DSD_STI_Age_Sex_ Result 40-49, Male, Negative	329
	HTS_TST_N_DSD_STI_Age_Sex_ Result 40-49, Male, Positive	48
	HTS_TST_N_DSD_TBC_Age_Sex_ Result 25-29, Female, Negative	1,876
	HTS_TST_N_DSD_TBC_Age_Sex_ Result 25-29, Female, Positive	199
	HTS_TST_N_DSD_TBC_Age_Sex_ Result 25-29, Male, Negative	1,582
	HTS_TST_N_DSD_TBC_Age_Sex_ Result 25-29, Male, Positive	168
	HTS_TST_N_DSD_TBC_Age_Sex_ Result 30-34, Female, Negative	1,830
	HTS_TST_N_DSD_TBC_Age_Sex_ Result 30-34, Female, Positive	339
	HTS_TST_N_DSD_TBC_Age_Sex_ Result 30-34, Male, Negative	1,587
	HTS_TST_N_DSD_TBC_Age_Sex_ Result 30-34, Male, Positive	280
	HTS_TST_N_DSD_TBC_Age_Sex_ Result 35-39, Female, Negative	1,609
	HTS_TST_N_DSD_TBC_Age_Sex_ Result 35-39, Female, Positive	354
	HTS_TST_N_DSD_TBC_Age_Sex_ Result 35-39, Male, Negative	2,060
	HTS_TST_N_DSD_TBC_Age_Sex_ Result 35-39, Male, Positive	350
	HTS_TST_N_DSD_TBC_Age_Sex_ Result 40-49, Female, Negative	1,786



	HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Female, Positive	424
	HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Male, Negative	2,805
	HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Male, Positive	280
	HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Female, Negative	159,505
	HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Female, Positive	9,900
	HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Male, Negative	85,022
	HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Male, Positive	2,148
	HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Female, Negative	103,642
	HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Female, Positive	6,215
	HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Male, Negative	76,019
	HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Male, Positive	3,187
	HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Female, Negative	75,340
	HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Female, Positive	5,621
	HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Male, Negative	62,621
	HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Male, Positive	4,123
	HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Female, Negative	60,127
	HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Female, Positive	7,329

	HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Male, Negative	65,748
	HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Male, Positive	6,553
GEND_GBV_DSD	Number of people receiving post-GBV care	30,253
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	18,769
	By type of service: Sexual Violence (Post-Rape Care)	11,465
	By PEP service provision (related to sexual violence services provided)	10,326
	<10, Female, Physical and/or Emotional Violence	1,237
	<10, Female, Sexual Violence (Post-Rape Care)	1,125
	<10, Male, Physical and/or Emotional Violence	450
	<10, Male, Sexual Violence (Post-Rape Care)	108
	10-14, Female, Physical and/or Emotional Violence	1,027
	10-14, Female, Sexual Violence (Post-Rape Care)	1,581
	10-14, Male, Physical and/or Emotional Violence	463
	10-14, Male, Sexual Violence (Post-Rape Care)	122
	15-19, Female, Physical and/or Emotional Violence	1,496
	15-19, Female, Sexual Violence (Post-Rape Care)	1,240

	15-19, Male, Physical and/or Emotional Violence	379
	15-19, Male, Sexual Violence (Post-Rape Care)	184
	20-24, Female, Physical and/or Emotional Violence	2,516
	20-24, Female, Sexual Violence (Post-Rape Care)	2,800
	20-24, Male, Physical and/or Emotional Violence	1,472
	20-24, Male, Sexual Violence (Post-Rape Care)	489
	50+, Female, Physical and/or Emotional Violence	220
	50+, Female, Sexual Violence (Post-Rape Care)	50
	50+, Male, Physical and/or Emotional Violence	28
	50+, Male, Sexual Violence (Post-Rape Care)	8
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	3,735
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	1,497
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	920
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	337
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female,	1,482

	Physical and/or Emotional Violence	
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	586
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	346
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	123
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	1,102
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	428
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	260
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	94
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	1,102
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	428
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	260
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	92
OVC_SERV_DSD	Number of active beneficiaries	940,068

	served by PEPFAR OVC programs for children and families affected by HIV/AIDS	
	Age/Sex: 10-14 Male	111,000
	Age/Sex: 15-17 Male	51,865
	By: Age/sex: Male 18-24	17,178
	By: Age/sex: Male 25+	31,693
	Age/Sex: 10-14 Female	107,506
	Age/Sex: 15-17 Female	50,336
	By: Age/sex: 18-24 Female	16,299
	By: Age/sex: 25+ Female	163,026
	Sum of Age/Sex disaggregates	320,707
	Age/Sex: <1	19,727
	Age/Sex: 1-9	371,425
	Program Completion: Active	912,687
	Program Completion: Graduation	27,381
OVC_HIVSTAT_DSD	OVC_HIVSTAT_DSD Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	76 %
	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	711,872
	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	940,068
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and	10,233

	relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	102
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4,882
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	126
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	5,186
TB_PREV_DSD	TB_PREV_DSD TB_PREV_DSD	90 %
	The number of ART patients who completed a course of TB preventive therapy or at least 6	551,150

	months of Isoniazid Preventive Therapy (IPT) during the reporting period	
	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	612,378
	By Age/Sex (Denominator): <15, Female	5,580
	By Age/Sex (Denominator): <15, Male	5,913
	By Age/Sex (Denominator): 15+, Female	417,707
	By Age/Sex (Denominator): 15+, Male	183,254
	By Age/Sex (Numerator): <15, Female	7,800
	By Age/Sex (Numerator): <15, Male	6,040
	By Age/Sex (Numerator): 15+, Female	367,824
	By Age/Sex (Numerator): 15+, Male	169,472
	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	581,798
	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	30,637

	TB_PREV_N_DSD_TherapyType_ NewExArt_HIV IPT, Life-long ART, Already, Positive	523,608
	TB_PREV_N_DSD_TherapyType_ NewExArt_HIV IPT, Life-long ART, New, Positive	27,599
TX_TB_DSD	TX_TB_DSD The proportion of ART patients who were screened who are receiving TB treatment	0 %
	Number of ART patients who were screened for TB at least once during the reporting period	965,958
	Denominator: By Aggregated Age/Sex: <15, Female	26,398
	Denominator: By Aggregated Age/Sex: <15, Male	25,479
	Denominator: By Aggregated Age/Sex: 15+, Female	643,142
	Denominator: By Aggregated Age/Sex: 15+, Male	270,953
	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	771,348
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	771,348
	TX_TB_D_DSD_TBScreen_NewEx istingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	476,355
	TX_TB_D_DSD_TBScreen_NewEx istingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	119,170

	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	317,626
	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	52,979
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	34,330
	By infants who received a virologic test within 2 months of birth	27,476
	By infants who received their first virologic HIV test between 2 and 12 months of age	6,854
	Sum of Infant Age disaggregates	34,330
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	966,087
	Age/Sex: 15-19 Male	5,304
	Age/Sex: 15-19 Female	10,884
	Age/Sex: <1	340
	Age/Sex: <1-9	28,839
	Age/Sex: 10-14 Male	8,219
	Age/Sex: 10-14 Female	8,078
	Age/Sex: 20-24 Male	8,811
	Age/Sex: 50+ Male	66,842
	Age/Sex: 20-24 Female	42,824
	Age/Sex: 50+ Female	81,872
	TX_CURR_N_DSD_Age_Sex_HIV Status 25-29, Female, Positive	83,377

	TX_CURR_N_DSD_Age_Sex_HIV Status 25-29, Male, Positive	27,683
	TX_CURR_N_DSD_Age_Sex_HIV Status 30-34, Female, Positive	129,324
	TX_CURR_N_DSD_Age_Sex_HIV Status 30-34, Male, Positive	29,677
	TX_CURR_N_DSD_Age_Sex_HIV Status 35-39, Female, Positive	134,380
	TX_CURR_N_DSD_Age_Sex_HIV Status 35-39, Male, Positive	41,961
	TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Female, Positive	168,815
	TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Male, Positive	89,327
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	150,663
	By Age/Sex: <1	730
	By Age/Sex: 1-9	4,841
	By Age/Sex: 10-14 Male	950
	By Age/Sex: 15-19 Male	928
	By Age/Sex: 20-24 Male	6,201
	By Age/Sex: 50+ Male	5,952
	By Age/Sex: 10-14 Female	1,177
	By Age/Sex: 15-19 Female	3,466
	By Age/Sex: 20-24 Female	18,778
	By Age/Sex: 50+ Female	7,049
	Pregnancy status	7,086
	Breastfeeding status	1,304
	FSW	7,841
	MSM	3,461
	TG	13
	By Key populations: People who	1,159



	inject drugs (PWID)	
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 25-29, Female, Positive	18,861
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 25-29, Male, Positive	8,609
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 30-34, Female, Positive	12,186
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 30-34, Male, Positive	5,404
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 35-39, Female, Positive	15,005
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 35-39, Male, Positive	6,807
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 40-49, Female, Positive	23,191
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 40-49, Male, Positive	10,636
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	0 %
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	947,079
	Denominator: Indication: Routine	922,931
	Denominator: Indication: Targeted	23,996
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	783
	Denominator: Aggregate Age/Sex	6,206

	by Indication: 15+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	796
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	16,199
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	19,181
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	264,723
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	17,216
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	621,808
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	90 %
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	142,040
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	157,811
	Numerator by Status: Pregnant	6,693
	Numerator by Status: Breastfeeding	1,149
	Denominator by Status: Pregnant	7,401
	Denominator by Status: Breastfeeding	1,280
	Aggregated Age/Sex: <15 Male	3,961



	(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	40,787
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,865
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	93,294
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,407
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	46,792
	Aggregated Age/Sex: <15 Female	4,292

	(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	102,217



Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
10004	Association of Public Health Laboratories	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
10015	National Blood Transfusion Service of Nigeria	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
10019	Safe Blood for Africa Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
12831	African Field Epidemiology Network	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		

13713	Medical Laboratories Science Council of Nigeria	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
14055	Management Sciences for Health	NGO	U.S. Agency for International Development		
14064	IntraHealth International, Inc	NGO	U.S. Agency for International Development		
14169	Abt Associates	Private Contractor	U.S. Agency for International Development		
14298	Deloitte Consulting Limited	Private Contractor	U.S. Agency for International Development		
14302	John Snow Inc (JSI)	Implementing Agency	U.S. Agency for International Development		
14505	FHI 360	NGO	U.S. Agency for International Development		
14664	Heartland Alliance for Human Needs and Human Rights	NGO	U.S. Agency for International Development		
14666	TBD	TBD	Redacted	Redacted	Redacted
14768	Partnership for Supply Chain Management	Private Contractor	U.S. Agency for International Development		
16797	Pathfinder International	NGO	U.S. Agency for International		



			Development		
16827	Center for Integrated Health Programs	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
16828	AIDS Prevention Initiative in Nigeria, LTD	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
16838	University of Maryland Baltimore	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
16839	Institute of Human Virology, Nigeria	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
16848	Catholic Caritas Foundation of Nigeria (CCFN)	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		



16850	AIDS Prevention Initiative in Nigeria, LTD	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
16852	African Society for Laboratory Medicine	NGO	U.S. Agency for International Development		
16853	Center for Clinical Care and Clinical Research Ltd	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
16854	Center for Clinical Care and Clinical Research Ltd	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
16855	Center for Integrated Health Programs	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
16871	Institute of Human Virology, Nigeria	NGO	U.S. Department of Health and Human Services/Centers for Disease		



			Control and Prevention		
17195	Health Initiatives for Safety and Stability in Africa	NGO	U.S. Department of Defense		
17727	Management Sciences for Health	NGO	U.S. Agency for International Development		
17728	Catholic Relief Services	FBO	U.S. Agency for International Development		
17729	Save the Children US	NGO	U.S. Agency for International Development	GHP-State	75,340
17733	John Snow Inc (JSI)	Implementing Agency	U.S. Agency for International Development		
17734	KNCV Tuberculosis Foundation	NGO	U.S. Agency for International Development		
17735	Society for Family Health-Nigeria	Private Contractor	U.S. Agency for International Development		
17737	Health Initiatives for Safety and Stability in Africa	NGO	U.S. Agency for International Development	GHP-State	99,523
17739	United Nations Children's Fund	Multi-lateral Agency	U.S. Agency for International Development		
17742	Friends for Global Health Initiative in Nigeria	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and		



			Prevention		
17743	[Placeholder]	TBD	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
17744	Excellence Community Education Welfare Scheme (ECEWS)	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
17745	Achieving Health Nigeria Initiative	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
17747	Henry Jackson Foundation	Private Contractor	U.S. Department of Defense		
18010	Association for Reproductive and Family Health	NGO	U.S. Agency for International Development	GHP-State	936,621
18070	DevTech Systems Inc	Private Contractor	U.S. Agency for International Development		
18075	Widows and Orphans Empowerment Organization	NGO	U.S. Agency for International Development	GHP-State	389,190
18076	Dexis Consulting	Private Contractor	U.S. Agency for		

	Group		International Development		
18127	University of North Carolina at Chapel Hill, Carolina Population Center	University	U.S. Agency for International Development		
18128	Catholic Relief Services	FBO	U.S. Agency for International Development		
18438	AFENET CDC HQ	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
18439	University of Maryland Baltimore	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,171,971
18441	Management Sciences for Health	NGO	U.S. Agency for International Development		
18442	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-State, GHP-USAID	98,441,799
18615	APIN Public Health Initiatives Ltd/Gte	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and	GHP-State	25,849,145

			Prevention		
18644	Kheth'Impilo	NGO	U.S. Agency for International Development		
18645	Health Research Inc./New York State Department of Health	Other USG Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
18647	Palladium Group	NGO	U.S. Agency for International Development		
18648	JHPIEGO	University	U.S. Agency for International Development		
18655	TBD	TBD	Redacted	Redacted	Redacted
18656	TBD	TBD	Redacted	Redacted	Redacted
18657	TBD	TBD	Redacted	Redacted	Redacted
18661	TBD	TBD	Redacted	Redacted	Redacted
18662	FHI 360	NGO	U.S. Agency for International Development		
18663	TBD	TBD	Redacted	Redacted	Redacted
18664	American Society for Microbiology	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
18675	Institute of Human Virology, Nigeria	NGO	U.S. Department of Health and Human	GHP-State	18,792,118



			Services/Centers for Disease Control and Prevention		
18676	Catholic Caritas Foundation of Nigeria (CCFN)	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	5,806,210
18677	Center for Integrated Health Programs	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	5,881,634
70254	[Placeholder]	TBD	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
70255	TBD	TBD	Redacted	Redacted	Redacted
70256	[Placeholder]	TBD	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
70257	[Placeholder]	TBD	U.S. Department of Health and Human		

			Services/Centers for Disease Control and Prevention		
70258	[Placeholder]	TBD	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
70259	[Placeholder]	TBD	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
70260	[Placeholder]	TBD	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
70261	[Placeholder]	TBD	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
70262	[Placeholder]	TBD	U.S. Department of Health and Human Services/Centers		

			for Disease Control and Prevention		
70263	[Placeholder]	TBD	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
70264	[Placeholder]	TBD	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
70265	[Placeholder]	TBD	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
70266	[Placeholder]	TBD	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
70267	TBD	TBD	Redacted	Redacted	Redacted
70268	TBD	TBD	Redacted	Redacted	Redacted
70269	TBD	TBD	Redacted	Redacted	Redacted
70270	TBD	TBD	Redacted	Redacted	Redacted

Approved



70271	TBD	TBD	Redacted	Redacted	Redacted
70272	TBD	TBD	Redacted	Redacted	Redacted
70273	TBD	TBD	Redacted	Redacted	Redacted
70274	TBD	TBD	Redacted	Redacted	Redacted
70275	TBD	TBD	Redacted	Redacted	Redacted
70276	TBD	TBD	Redacted	Redacted	Redacted
70512	[Placeholder]	TBD	U.S. Department of State/Office of the Global AIDS Coordinator		



Implementing Mechanism(s)

Implementing Mechanism Details

Mechanism ID: 10004	Mechanism Name: APHL's Partnership with HHS/CDC to assist PEPFAR Build Quality Laboratory Capacity_799
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Association of Public Health Laboratories	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	10004	
Mechanism Name:	APHL's Partnership with HHS/CDC to assist PEPFAR Build Quality Laboratory Capacity_799	
Prime Partner Name:	Association of Public Health Laboratories	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0



Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 10015	Mechanism Name: National Blood Transfusion Service (NBTS)_997
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: National Blood Transfusion Service of Nigeria	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	



Funding Source	Funding Amount
----------------	----------------

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 10015 Mechanism Name: National Blood Transfusion Service (NBTS)_997 Prime Partner Name: National Blood Transfusion Service of Nigeria		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount



Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 10019	Mechanism Name: Safe Blood for Africa Foundation
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Safe Blood for Africa Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	10019	
Mechanism Name:	Safe Blood for Africa Foundation	
Prime Partner Name:	Safe Blood for Africa Foundation	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12831	Mechanism Name: Improving the quality of health service delivery through training support for epidemiology, M&E, survey and laboratory services_431
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Field Epidemiology Network	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	



Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 12831 Mechanism Name: Improving the quality of health service delivery through training support for epidemiology, M&E, survey and laboratory services_431 Prime Partner Name: African Field Epidemiology Network		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13713	Mechanism Name: Mentoring Laboratories Towards National Accreditation (MELTNA)_090
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Medical Laboratories Science Council of Nigeria	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13713	
Mechanism Name:	Mentoring Laboratories Towards National Accreditation (MELTNA)_090	
Prime Partner Name:	Medical Laboratories Science Council of Nigeria	
Strategic Area	Budget Code	Planned Amount



Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14055	Mechanism Name: PLAN-Health
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Management Sciences for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	



Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 14055 Mechanism Name: PLAN-Health Prime Partner Name: Management Sciences for Health		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0



Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14064	Mechanism Name: Capacity Plus
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: IntraHealth International, Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	14064	
Mechanism Name:	Capacity Plus	
Prime Partner Name:	IntraHealth International, Inc	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14169	Mechanism Name: Health Finance and Governance Project
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Abt Associates	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 14169 Mechanism Name: Health Finance and Governance Project Prime Partner Name: Abt Associates		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount



Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14298	Mechanism Name: Enhancing Nigerian Capacity for AIDS Prevention
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Deloitte Consulting Limited	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 14298		
Mechanism Name: Enhancing Nigerian Capacity for AIDS Prevention		
Prime Partner Name: Deloitte Consulting Limited		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0



Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount



Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14302	Mechanism Name: Strengthening High Impact Interventions for and AIDS-free Generation (Aids Free)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: John Snow Inc (JSI)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	14302	
Mechanism Name:	Strengthening High Impact Interventions for	
Prime Partner Name:	and AIDS-free Generation (Aids Free)	
	John Snow Inc (JSI)	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount



Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14505	Mechanism Name: STRENGTHENING INTERGRATED DELIVERY OF HIV/AIDS SERVICES(SIDHAS)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	14505	
Mechanism Name:	STRENGTHENING INTERGRATED DELIVERY OF HIV/AIDS SERVICES(SIDHAS)	
Prime Partner Name:	FHI 360	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14664	Mechanism Name: Integrated MARPs HIV Prevention Program (IMHIPP)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Heartland Alliance for Human Needs and Human Rights	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 14664 Mechanism Name: Integrated MARPs HIV Prevention Program (IMHIPP) Prime Partner Name: Heartland Alliance for Human Needs and Human Rights		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount



Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14666	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 14768	Mechanism Name: SUPPLY CHAIN MANAGEMENT SYSTEMS
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Partnership for Supply Chain Management	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	14768	
Mechanism Name:	SUPPLY CHAIN MANAGEMENT SYSTEMS	
Prime Partner Name:	Partnership for Supply Chain Management	
Strategic Area	Budget Code	Planned Amount



Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16797	Mechanism Name: Evidence To Action for strengthened Family Planning & Health Services for Women & Girls (E2A)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Pathfinder International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	16797	
Mechanism Name:	Evidence To Action for strengthened Family Planning & Health	
Prime Partner Name:	Services for Women & Girls (E2A)	
	Pathfinder International	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0



Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16827	Mechanism Name: Strengthening Skills and Competencies of Care Providers for Enhanced service Delivery (SCOPE)_944
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Center for Integrated Health Programs	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 16827



Mechanism Name: Strengthening Skills and Competencies of Care Providers for Prime Partner Name: Enhanced service Delivery (SCOPE)_944 Center for Integrated Health Programs		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16828	Mechanism Name: Capacitating Laboratories for Accreditation, Strengthening and Sustainability (CLASS)_667
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: AIDS Prevention Initiative in Nigeria, LTD	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	
Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	16828	
Mechanism Name:	Capacitating Laboratories for Accreditation, Strengthening and Sustainability (CLASS)_667	
Prime Partner Name:	AIDS Prevention Initiative in Nigeria, LTD	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16838	Mechanism Name: Nigerian Alliance for Health System Strengthening (NAHSS)_656
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Maryland Baltimore	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information



Mechanism ID:	16838	
Mechanism Name:	Nigerian Alliance for Health System Strengthening	
Prime Partner Name:	(NAHSS)_656	
	University of Maryland Baltimore	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16839	Mechanism Name: Strengthening Health Human Resources in Nigeria Group (SHARING)_902
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Institute of Human Virology, Nigeria	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	
Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	16839	
Mechanism Name:	Strengthening Health Human Resources in Nigeria Group	
Prime Partner Name:	(SHARING)_902	
	Institute of Human Virology, Nigeria	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16848	Mechanism Name: Sustainable HIV care and Treatment Action in Nigeria (SUSTAIN)_934
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Caritas Foundation of Nigeria (CCFN)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information



Mechanism ID:	16848	
Mechanism Name:	Sustainable HIV care and Treatment Action in Nigeria	
Prime Partner Name:	(SUSTAIN)_934	
	Catholic Caritas Foundation of Nigeria (CCFN)	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16850	Mechanism Name: Comprehensive AIDS Response Enhanced for Sustainability (CARES)_924
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: AIDS Prevention Initiative in Nigeria, LTD	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: Mechanism Name: Prime Partner Name:	16850 Comprehensive AIDS Response Enhanced for Sustainability (CARES)_924 AIDS Prevention Initiative in Nigeria, LTD	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount



Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16852	Mechanism Name: Development of a Laboratory Network and Society to Implement a Quality Systems_710
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: African Society for Laboratory Medicine	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID:	16852	
Mechanism Name:	Development of a Laboratory Network and Society to Implement	
Prime Partner Name:	a Quality Systems_710	
	African Society for Laboratory Medicine	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16853	Mechanism Name: Partnership for Medical Education and Training (PMET)_916
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement



Prime Partner Name: Center for Clinical Care and Clinical Research Ltd	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	
Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 16853		
Mechanism Name: Partnership for Medical Education and Training (PMET)_916		
Prime Partner Name: Center for Clinical Care and Clinical Research Ltd		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount



Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16854	Mechanism Name: Service Expansion and Early Detection for Sustainable HIV Care (SEEDS)_868
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Center for Clinical Care and Clinical Research Ltd	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID:	16854	
Mechanism Name:	Service Expansion and Early Detection for Sustainable HIV Care	
Prime Partner Name:	(SEEDS)_868	
	Center for Clinical Care and Clinical Research Ltd	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16855	Mechanism Name: Bridges Plus_928
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Center for Integrated Health Programs	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	
Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 16855		
Mechanism Name: Bridges Plus_928		
Prime Partner Name: Center for Integrated Health Programs		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16871	Mechanism Name: Action Plus-Up_925
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Institute of Human Virology, Nigeria	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 16871



Mechanism Name: Action Plus-Up_925		
Prime Partner Name: Institute of Human Virology, Nigeria		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17195	Mechanism Name: HIFASS
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Health Initiatives for Safety and Stability in Africa	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17195 Mechanism Name: HIFASS Prime Partner Name: Health Initiatives for Safety and Stability in Africa		
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17727	Mechanism Name: MSH - Prevention Organisation Systems AIDS Care and Treatment(MSH -ProACT)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Management Sciences for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	



G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17727	
Mechanism Name:	MSH - Prevention Organisation Systems AIDS Care and Treatment(MSH -ProACT)	
Prime Partner Name:	Management Sciences for Health	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0



Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17728	Mechanism Name: Sustainable Mechanism for Improving Livelihood & Household Empowerment (SMILE)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Relief Services	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17728
----------------------	--------------



Mechanism Name: Sustainable Mechanism for Improving Livelihood & Household Prime Partner Name: Empowerment (SMILE) Catholic Relief Services		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17729	Mechanism Name: Systems Transformed for Empowered Action and Enabling Responses for Vulnerable Children and Families (STEER)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Save the Children US	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 75,340	
Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 337,380	
Total All Funding Sources and Applied Pipeline Amount: 412,720	
Funding Source	Funding Amount
GHP-State	75,340

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17729	
Mechanism Name:	Systems Transformed for Empowered Action and Enabling	
Prime Partner Name:	Responses for Vulnerable Children and Families (STEER)	
	Save the Children US	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	75,340
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount



Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	11,595
OVC_SERV_DSD	Age/Sex: 10-14 Male	1,264
OVC_SERV_DSD	Age/Sex: 15-17 Male	626
OVC_SERV_DSD	By: Age/sex: Male 18-24	160
OVC_SERV_DSD	By: Age/sex: Male 25+	485
OVC_SERV_DSD	Age/Sex: 10-14 Female	1,334
OVC_SERV_DSD	Age/Sex: 15-17 Female	727
OVC_SERV_DSD	By: Age/sex: 18-24 Female	180
OVC_SERV_DSD	By: Age/sex: 25+ Female	2,307
OVC_SERV_DSD	Sum of Age/Sex disaggregates	3,951
OVC_SERV_DSD	Age/Sex: <1	224
OVC_SERV_DSD	Age/Sex: 1-9	4,286
OVC_SERV_DSD	Program Completion: Active	11,256
OVC_SERV_DSD	Program Completion: Graduation	339
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	8,461
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by	11,595



	HIV/AIDS	
--	----------	--

Implementing Mechanism Details

Mechanism ID: 17733	Mechanism Name: Strengthening Partnerships, Results and Innovations in Nutrition Globally (SPRING)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: John Snow Inc (JSI)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17733	
Mechanism Name:	Strengthening Partnerships, Results and Innovations in Nutrition Globally (SPRING)	
Prime Partner Name:	John Snow Inc (JSI)	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17734	Mechanism Name: Challenge TB
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: KNCV Tuberculosis Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17734 Mechanism Name: Challenge TB Prime Partner Name: KNCV Tuberculosis Foundation		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0



Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 17735	Mechanism Name: SHiPS for MARPs
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Society for Family Health-Nigeria	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17735		
Mechanism Name: SHiPS for MARPs		
Prime Partner Name: Society for Family Health-Nigeria		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0



Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount



Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17737	Mechanism Name: Local Partner for Orphans and Vulnerable Children 3
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Health Initiatives for Safety and Stability in Africa	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 99,523	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 193,672	
Total All Funding Sources and Applied Pipeline Amount: 293,195	
Funding Source	Funding Amount
GHP-State	99,523

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 17737 Mechanism Name: Local Partner for Orphans and Vulnerable Children 3 Prime Partner Name: Health Initiatives for Safety and Stability in Africa		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	99,523
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0



Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by	15,315



	HIV/AIDS	
OVC_SERV_DSD	Age/Sex: 10-14 Male	1,528
OVC_SERV_DSD	Age/Sex: 15-17 Male	815
OVC_SERV_DSD	By: Age/sex: Male 18-24	218
OVC_SERV_DSD	By: Age/sex: Male 25+	980
OVC_SERV_DSD	Age/Sex: 10-14 Female	1,604
OVC_SERV_DSD	Age/Sex: 15-17 Female	1,131
OVC_SERV_DSD	By: Age/sex: 18-24 Female	209
OVC_SERV_DSD	By: Age/sex: 25+ Female	2,868
OVC_SERV_DSD	Sum of Age/Sex disaggregates	5,078
OVC_SERV_DSD	Age/Sex: <1	203
OVC_SERV_DSD	Age/Sex: 1-9	5,760
OVC_SERV_DSD	Program Completion: Active	14,868
OVC_SERV_DSD	Program Completion: Graduation	447
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	11,042
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	15,315

Implementing Mechanism Details

Mechanism ID: 17739	Mechanism Name: UNICEF
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: United Nations Children's Fund	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	



Funding Source	Funding Amount
----------------	----------------

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17739 Mechanism Name: UNICEF Prime Partner Name: United Nations Children's Fund		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount



Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17742	Mechanism Name: Supporting Universal Comprehensive and Sustainable HIV/AIDS Services (SUCCESS)_922
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Friends for Global Health Initiative in Nigeria	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17742	
Mechanism Name:	Supporting Universal Comprehensive and Sustainable HIV/AIDS Services (SUCCESS)_922	
Prime Partner Name:	Friends for Global Health Initiative in Nigeria	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0



Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17743	Mechanism Name: Integrated Programs for Sustainable Action Against HIV/AIDS in Nigeria (IPSAN)_929
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	



Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17743	
Mechanism Name:	Integrated Programs for Sustainable Action Against HIV/AIDS in	
Prime Partner Name:	Nigeria (IPSAN)_929	
	[Placeholder]	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17744	Mechanism Name: Local Capacity Enhancement (LOCATE)_867
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Excellence Community Education Welfare Scheme (ECEWS)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17744	
Mechanism Name:	Local Capacity Enhancement (LOCATE)_867	
Prime Partner Name:	Excellence Community Education Welfare Scheme (ECEWS)	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17745	Mechanism Name: Sustaining Comprehensive HIV/AIDS Response through Partnerships (SCHARP+) _937
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Achieving Health Nigeria Initiative	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	



Funding Source	Funding Amount
----------------	----------------

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17745	
Mechanism Name:	Sustaining Comprehensive HIV/AIDS Response through	
Prime Partner Name:	Partnerships (SCHARP+) _937	
	Achieving Health Nigeria Initiative	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0



Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17747	Mechanism Name: Henry Jackson Foundation
Funding Agency: DOD	Procurement Type: Cooperative Agreement
Prime Partner Name: Henry Jackson Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17747	
Mechanism Name:	Henry Jackson Foundation	
Prime Partner Name:	Henry Jackson Foundation	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	801
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	14,222
PMTCT_ART_DSD	New on ART	180
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	621
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	14,222
PMTCT_STAT_DSD	Number of new ANC and L&D clients	15,007
PMTCT_STAT_DSD	By Age (Denominator): 10-14	28
PMTCT_STAT_DSD	By Age (Denominator): <15-19	450



PMTCT_STAT_DSD	By Age (Denominator): 20-24	2,895
PMTCT_STAT_DSD	By Age (Denominator): 50+	75
PMTCT_STAT_DSD	By Number of known positives: 10-14	1
PMTCT_STAT_DSD	By Number of known positives: 15-19	19
PMTCT_STAT_DSD	By Number of known positives: 20-24	126
PMTCT_STAT_DSD	By Number of known positives: 50+	3
PMTCT_STAT_DSD	By Number of new positives: 15-19	7
PMTCT_STAT_DSD	By Number of new positives: 20-24	38
PMTCT_STAT_DSD	By Number of new positives: 50+	1
PMTCT_STAT_DSD	By Number of new negative: 10-14	45
PMTCT_STAT_DSD	By Number of new negative: 15-19	402
PMTCT_STAT_DSD	By Number of new negative: 20-24	2,587
PMTCT_STAT_DSD	By Number of new negative: 50+	67
PMTCT_STAT_DSD	By Age (Numerator): 10-14	27
PMTCT_STAT_DSD	By Age (Numerator): 15-19	428
PMTCT_STAT_DSD	By Age (Numerator): 20-24	2,750
PMTCT_STAT_DSD	By Age (Numerator): 50+	71
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	5,753
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	3,910
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	1,565
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	331
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	239
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	5,140
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	96
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	182
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	3,494
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	55



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	80
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	1,398
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	33
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	10
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	296
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	5
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	5,465
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	3,715
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	1,486
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	314
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	23,776
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	18,083
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	3,857
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,836



HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	67,251
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	87
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	77
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	36
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	30
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	86
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	88
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	49
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	50
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	8



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	339
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	136
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	107
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	35
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	963
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	57
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	4,158
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	226
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	188
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	293
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	525
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	590
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14,	11



	Male, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	1,091
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	30
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	914
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	89
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	2,977
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	111
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	3,577
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	170
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	1,003
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	65
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	1,610
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	106
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	1,459
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	64
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	8
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	9
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	2



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	8
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	16
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	16
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	8
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	15
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	31
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	63
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	9
HTC_TST_DSD	By Key Population: FSW, Negative	4,181
HTC_TST_DSD	By Key Population: FSW, Positive	137
HTC_TST_DSD	By Key Population: MSM, Negative	4,408
HTC_TST_DSD	By Key Population: MSM, Positive	554
HTC_TST_DSD	By Key Population: PWID, Negative	1,996
HTC_TST_DSD	By Key Population: PWID, Positive	25
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	9
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	413
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	2,697
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	63
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	401
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female,	121



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	190
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	104
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	59
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	340
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	52
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	207
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	43
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	124
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	28
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	198
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	29
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	389
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	22
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14,	5



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Male, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Male, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Negative	12
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Negative	7
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Negative	18
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Negative	17
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Negative	12
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Negative	22
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Negative	17
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Negative	1



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Negative	12
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	77
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	29
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	38
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	34
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	61
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	115
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	100
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	22
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	107
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	39
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49,	92



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	84
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	29
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	80
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	30
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	91
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	91
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	70
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	141
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	121
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49,	40



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	839
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	71
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	1,259
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	149
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	629
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	35
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	839
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	42
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	105
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	105
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	35
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	420
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	420
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	4,264
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29,	170



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	3,655
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	191
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	2,436
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	255
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	1,827
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	106
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	1,218
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	213
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	1,523
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	128
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	1,827
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	319
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	2,436
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	170
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	4,280
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	54
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34,	1,873



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	34
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	2,140
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	47
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	1,605
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	33
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	579
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	33
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	386
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	47
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	38
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	482
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	43
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	321
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	38
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	321
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49,	38

	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	96
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	43
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	890
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	890
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	22
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	523
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	34
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	311
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	22
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	523
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	34
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	311
GEND_GBV_DSD	Number of people receiving post-GBV care	330

GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	177
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	153
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	138
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	7
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	8
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	1
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	3
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	10
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	10
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	2
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	4
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	11
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	12
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	1
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	8
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	20
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	50
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	4
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	27
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	1
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	43
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	12
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	16
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	3
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	17

GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	5
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	6
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	13
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	3
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	5
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	13
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	3
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	5
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	1
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	315
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	98
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	216
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within	762

	12 months of birth during the reporting period	
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	610
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	152
PMTCT_EID_DSD	Sum of Infant Age disaggregates	762
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	32,156
TX_CURR_DSD	Age/Sex: 15-19 Male	208
TX_CURR_DSD	Age/Sex: 15-19 Female	179
TX_CURR_DSD	Sum of age/sex disaggregates	387
TX_CURR_DSD	Age/Sex: <1	16
TX_CURR_DSD	Age/Sex: <1-9	594
TX_CURR_DSD	Age/Sex: 10-14 Male	286
TX_CURR_DSD	Age/Sex: 10-14 Female	269
TX_CURR_DSD	Age/Sex: 20-24 Male	651
TX_CURR_DSD	Age/Sex: 50+ Male	2,724
TX_CURR_DSD	Age/Sex: 20-24 Female	579
TX_CURR_DSD	Age/Sex: 50+ Female	2,412
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	2,617
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	1,181
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	4,061
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	1,265
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	4,219
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	1,788
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	5,300

TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	3,808
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,697
TX_NEW_DSD	By Age/Sex: <1	26
TX_NEW_DSD	By Age/Sex: 1-9	99
TX_NEW_DSD	By Age/Sex: 10-14 Male	5
TX_NEW_DSD	By Age/Sex: 20-24 Male	82
TX_NEW_DSD	By Age/Sex: 50+ Male	150
TX_NEW_DSD	By Age/Sex: 10-14 Female	16
TX_NEW_DSD	By Age/Sex: 15-19 Female	218
TX_NEW_DSD	By Age/Sex: 20-24 Female	340
TX_NEW_DSD	By Age/Sex: 50+ Female	177
TX_NEW_DSD	Sum of Age/Sex disaggregates	988
TX_NEW_DSD	Pregnancy status	123
TX_NEW_DSD	Breastfeeding status	12
TX_NEW_DSD	FSW	142
TX_NEW_DSD	MSM	391
TX_NEW_DSD	By Key populations: People who inject drugs (PWID)	36
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	469
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	238
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	295
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	150
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	371
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	188
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	579

TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	294
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	32,111
TX_PVLS_DSD	Denominator: Indication: Routine	31,384
TX_PVLS_DSD	Denominator: Indication: Targeted	727
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	17
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	201
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	17
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	492
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	709
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	9,224
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	624
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	20,827
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,407
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	3,785
TX_RET_DSD	Numerator by Status: Pregnant	118
TX_RET_DSD	Numerator by Status: Breastfeeding	12
TX_RET_DSD	Denominator by Status: Pregnant	131
TX_RET_DSD	Denominator by Status: Breastfeeding	13
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of	68



	adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,400
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	66
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,872
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	76
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,563
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	73
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,073
HTS_SELF_DSD	HTS_SELF_N_DSD	20
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Directly-Assisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14,	1



	Female, Unassisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	10

HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	10
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	1
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	2
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	2
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Unassisted	1
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	18,738
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	20,820
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	158
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	53
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	15,352
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	5,258
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	598
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	199
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	11,961
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	5,980
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	19,779
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	1,041



TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	17,802
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	938
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	32,156
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	1,071
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	1,282
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	21,015
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	8,789
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	25,726
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	25,726
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	17,109
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	2,792
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	11,405
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	850

Implementing Mechanism Details

Mechanism ID: 18010	Mechanism Name: Local Partners for Orphans & Vulnerable Children 1
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Association for Reproductive and Family Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



Total All Funding Sources: 936,621	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 88,028	
Total All Funding Sources and Applied Pipeline Amount: 1,024,649	
Funding Source	Funding Amount
GHP-State	936,621

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18010	
Mechanism Name:	Local Partners for Orphans & Vulnerable Children 1	
Prime Partner Name:	Association for Reproductive and Family Health	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	936,621
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0



Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	144,120
OVC_SERV_DSD	Age/Sex: 10-14 Male	15,844
OVC_SERV_DSD	Age/Sex: 15-17 Male	7,798
OVC_SERV_DSD	By: Age/sex: Male 18-24	2,457
OVC_SERV_DSD	By: Age/sex: Male 25+	6,440
OVC_SERV_DSD	Age/Sex: 10-14 Female	15,895
OVC_SERV_DSD	Age/Sex: 15-17 Female	8,150
OVC_SERV_DSD	By: Age/sex: 18-24 Female	3,092
OVC_SERV_DSD	By: Age/sex: 25+ Female	26,957
OVC_SERV_DSD	Sum of Age/Sex disaggregates	47,687
OVC_SERV_DSD	Age/Sex: <1	3,140
OVC_SERV_DSD	Age/Sex: 1-9	54,346
OVC_SERV_DSD	Program Completion: Active	139,924
OVC_SERV_DSD	Program Completion: Graduation	4,196
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	105,173
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	144,120

Implementing Mechanism Details

Mechanism ID: 18070	Mechanism Name: Monitoring, Evaluation & Learning Program (MEL)
----------------------------	--



Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: DevTech Systems Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18070 Mechanism Name: Monitoring, Evaluation & Learning Program (MEL) Prime Partner Name: DevTech Systems Inc		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount



Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18075	Mechanism Name: Local Partners for Orphans & Vulnerable Children 2
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Widows and Orphans Empowerment Organization	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 389,190	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 154,319	
Total All Funding Sources and Applied Pipeline Amount: 543,509	
Funding Source	Funding Amount
GHP-State	389,190

Cross-Cutting Budget Attribution(s)

(No data provided.)

**Budget Code Information**

Mechanism ID: 18075		
Mechanism Name: Local Partners for Orphans & Vulnerable Children 2		
Prime Partner Name: Widows and Orphans Empowerment Organization		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	389,190
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	59,886



OVC_SERV_DSD	Age/Sex: 10-14 Male	6,768
OVC_SERV_DSD	Age/Sex: 15-17 Male	3,490
OVC_SERV_DSD	By: Age/sex: Male 18-24	823
OVC_SERV_DSD	By: Age/sex: Male 25+	2,277
OVC_SERV_DSD	Age/Sex: 10-14 Female	6,911
OVC_SERV_DSD	Age/Sex: 15-17 Female	3,707
OVC_SERV_DSD	By: Age/sex: 18-24 Female	1,349
OVC_SERV_DSD	By: Age/sex: 25+ Female	9,543
OVC_SERV_DSD	Sum of Age/Sex disaggregates	20,876
OVC_SERV_DSD	Age/Sex: <1	1,211
OVC_SERV_DSD	Age/Sex: 1-9	23,808
OVC_SERV_DSD	Program Completion: Active	58,142
OVC_SERV_DSD	Program Completion: Graduation	1,744
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	45,895
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	59,886

Implementing Mechanism Details

Mechanism ID: 18076	Mechanism Name: Global Health Program Cycle Improvement Project (GH Pro)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Dexis Consulting Group	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	



Funding Source	Funding Amount
----------------	----------------

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18076 Mechanism Name: Global Health Program Cycle Improvement Project (GH Pro) Prime Partner Name: Dexis Consulting Group		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount



Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18127	Mechanism Name: Measure Evaluation IV
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University of North Carolina at Chapel Hill, Carolina Population Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18127	
Mechanism Name:	Measure Evaluation IV	
Prime Partner Name:	University of North Carolina at Chapel Hill, Carolina Population Center	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18128	Mechanism Name: Coordinating Comprehensive Care for Children - 4 Children
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Relief Services	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18128 Mechanism Name: Coordinating Comprehensive Care for Children - 4 Children Prime Partner Name: Catholic Relief Services		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount



Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18438	Mechanism Name: Strengthening Applied Epidemiology and sustainable international public health capacity through FETP_1619
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: AFENET CDC HQ	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18438	
Mechanism Name:	Strengthening Applied Epidemiology and sustainable international public health capacity through FETP_1619	
Prime Partner Name:	AFENET CDC HQ	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18439	Mechanism Name: Strengthening HIV Field Epidemiology, Infectious Disease Surveillance, and Lab Diagnostics Program (SHIELD)_1976
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Maryland Baltimore	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 1,171,971	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,171,971	



Funding Source	Funding Amount
GHP-State	1,171,971

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18439	
Mechanism Name:	Strengthening HIV Field Epidemiology, Infectious Disease Surveillance, and Lab Diagnostics Program (SHIELD)_1976	
Prime Partner Name:	University of Maryland Baltimore	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	1,171,971
Strategic Area	Budget Code	Planned Amount



Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18441	Mechanism Name: Care and Treatment in Sustained Support (CaTSS)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Management Sciences for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18441	
Mechanism Name:	Care and Treatment in Sustained Support (CaTSS)	
Prime Partner Name:	Management Sciences for Health	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18442	Mechanism Name: Global Health Supply Chain Program
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 98,441,799	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 36,817,528	
Total All Funding Sources and Applied Pipeline Amount: 135,259,327	
Funding Source	Funding Amount



GHP-State	73,441,799
GHP-USAID	25,000,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18442 Mechanism Name: Global Health Supply Chain Program Prime Partner Name: Global Health Supply Chain Program		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	974,008
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	974,008
Strategic Area	Budget Code	Planned Amount
Care	PDCS	974,008
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	867,858



Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	22,507
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	150,623
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	84,738,706
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	9,740,081
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18615	Mechanism Name: Improving Comprehensive AIDS Response Enhanced for Sustainability (iCARES) 2098
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: APIN Public Health Initiatives Ltd/Gte	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 25,849,145	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 25,849,145	
Funding Source	Funding Amount
GHP-State	25,849,145

Cross-Cutting Budget Attribution(s)

Gender: GBV	959,693
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Gender: Gender Equality	206,000
Focus Area:	Equity in HIV prevention, care, treatment and



	support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Food and Nutrition: Commodities	72,896
Water	80,055
Economic Strengthening	340,179
Food and Nutrition: Policy, Tools, and Service Delivery	42,588
Education	14,580

Budget Code Information

Mechanism ID: Mechanism Name: Prime Partner Name:	18615 Improving Comprehensive AIDS Response Enhanced for Sustainability (iCARES)_2098 APIN Public Health Initiatives Ltd/Gte	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	1,488,515
Strategic Area	Budget Code	Planned Amount
Care	HKID	10,712,834
Strategic Area	Budget Code	Planned Amount
Care	HVTB	199,163
Strategic Area	Budget Code	Planned Amount
Care	PDCS	492,703



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	322,575
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	1,750,532
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	1,618,479
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	1,045,413
Strategic Area	Budget Code	Planned Amount



Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	7,925,390
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	293,541

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	10,686
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	338,248
PMTCT_ART_DSD	New on ART	3,451
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	7,235
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	338,248
PMTCT_STAT_DSD	Number of new ANC and L&D clients	356,785
PMTCT_STAT_DSD	By Age (Denominator): 10-14	675
PMTCT_STAT_DSD	By Age (Denominator): <15-19	14,210
PMTCT_STAT_DSD	By Age (Denominator): 20-24	72,206
PMTCT_STAT_DSD	By Age (Denominator): 50+	1,783
PMTCT_STAT_DSD	By Number of known positives: 15-19	317
PMTCT_STAT_DSD	By Number of known positives: 20-24	1,654
PMTCT_STAT_DSD	By Number of known positives: 50+	14
PMTCT_STAT_DSD	By Number of new positives: 15-19	130
PMTCT_STAT_DSD	By Number of new positives: 20-24	661

PMTCT_STAT_DSD	By Number of new positives: 50+	13
PMTCT_STAT_DSD	By Number of new negative: 10-14	597
PMTCT_STAT_DSD	By Number of new negative: 15-19	13,009
PMTCT_STAT_DSD	By Number of new negative: 20-24	66,256
PMTCT_STAT_DSD	By Number of new negative: 50+	1,641
PMTCT_STAT_DSD	By Age (Numerator): 10-14	633
PMTCT_STAT_DSD	By Age (Numerator): 15-19	13,511
PMTCT_STAT_DSD	By Age (Numerator): 20-24	68,600
PMTCT_STAT_DSD	By Age (Numerator): 50+	1,699
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	133,341
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	90,625
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	36,276
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	7,669
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	2,940
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	122,502
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	1,194
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	1,993
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	83,259
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	810
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	767
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	33,314
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	251
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	142

PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	7,024
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	32
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	126,661
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	86,100
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	34,451
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	7,284
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	61,614
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	15,452
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	45,017
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,145
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,595,607
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	1,749
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	33
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male,	1,836



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	26
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	1,930
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	39
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	1,203
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	3,637
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	167
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	2,027
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	47
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	2,227
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	136
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	2,275
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	92
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	5,372
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	108
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	2,267
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	75
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing:	1,386



	15-19, Male, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	59
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	9,642
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	944
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	4,182
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	515
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	1,571
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	88
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	1,438
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	26,528
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	271
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	25,463
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	285
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	43,546
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	479
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	29,745
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19,	144



	Male, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	93,034
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	2,588
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	60,663
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	753
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	28,667
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	632
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	23,325
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	407
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	52,847
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	528
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	14,871
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	143
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	384
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	355
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female,	339



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	33
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	416
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	37
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	379
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	439
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	438
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	296
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	54
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	190
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	634
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	585
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female,	598



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	34
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	417
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	550
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	279
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	1,955
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	507
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	152
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	59
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	480
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	181
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	2,357
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	36
HTC_TST_DSD	By Key Population: FSW, Negative	31,082
HTC_TST_DSD	By Key Population: FSW, Positive	1,827
HTC_TST_DSD	By Key Population: MSM, Negative	5,495
HTC_TST_DSD	By Key Population: MSM, Positive	651
HTC_TST_DSD	By Key Population: PWID, Negative	6,052
HTC_TST_DSD	By Key Population: PWID, Positive	282
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	14



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	23
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	29
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	35
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	43
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	43
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	45
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	12
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	108
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	11,564
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 1-9, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	64,784
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	838
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	24
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	14,798



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	354
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	13,811
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	370
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	15,207
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	340
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	8,259
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	169
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	27,978
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	1,358
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	14,928
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	396
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	9,628
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	774
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	9,050
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	414
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	14,838
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	370



HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Female, Negative	800
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Male, Negative	800
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Negative	436
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Male, Negative	232
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 1-9, Unknown Sex, Negative	2,400
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 1-9, Unknown Sex, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Negative	326
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Negative	1,160
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Negative	435
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Negative	1,197
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Negative	544
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Negative	979
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Positive	13



HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Negative	762
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Positive	75
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Negative	1,197
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Positive	34
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Negative	762
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Positive	40
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Negative	982
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Negative	653
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Negative	1,197
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	667
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	416
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	361
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	332
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	667



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	249
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	1,089
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	104
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	1,112
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	416
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	1,329
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	332
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	775
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	249
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	722
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	227
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	3,587
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	228
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	2,925
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	2,715
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	151
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	1,822



HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	2,502
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	323
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	1,979
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	176
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	2,825
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	157
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	2,217
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	298
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	10,147
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	1,368
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	4,784
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	270
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	3,284
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	320
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	1,784
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	88
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	1,823



HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	180
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	742
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	40
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	1,725
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	33
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	727
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	26
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	35
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	8
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	11
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	4



HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	115,821
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	1,877
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	69,902
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	963
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	63,921
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	1,879
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	56,643
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	484
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	50,898
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	1,410
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	41,283



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	964
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	43,558
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	2,350
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	34,993
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	1,211
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	126,399
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	1,887
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	83,973
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	262
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	31,702
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	260
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	6,865
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	194
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	333
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	210



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	161
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	115
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	206
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	288
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	209
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	325
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	375
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	334
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	330



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	384
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	445
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	394
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	43
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	541
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	23,708
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	1,825
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	11,896
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	347
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	15,380
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	1,122
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	10,588
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	536



HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	11,094
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	988
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	7,954
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	672
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	8,115
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	1,310
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	7,454
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	1,261
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	8,363
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	8,363
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	265
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	4,522
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	227
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,352
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases,	265



	during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	4,522
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	227
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	3,352
GEND_GBV_DSD	Number of people receiving post-GBV care	6,354
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	4,307
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	2,043
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	1,843
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	101
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	131
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	204
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	31
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	128
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	211
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	74
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	30
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	269
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	238
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	44
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	32
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	456
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	445
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	190
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	86
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	41

GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	29
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	16
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	1,185
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	338
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	159
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	38
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	471
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	134
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	52
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	14
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	348
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	94
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	39
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	9
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	348
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	94
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	39
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3	9



	40-49, Male, Sexual Violence (Post-Rape Care)	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	349,794
OVC_SERV_DSD	Age/Sex: 10-14 Male	44,225
OVC_SERV_DSD	Age/Sex: 15-17 Male	20,072
OVC_SERV_DSD	By: Age/sex: Male 18-24	7,600
OVC_SERV_DSD	By: Age/sex: Male 25+	12,824
OVC_SERV_DSD	Age/Sex: 10-14 Female	41,194
OVC_SERV_DSD	Age/Sex: 15-17 Female	16,772
OVC_SERV_DSD	By: Age/sex: 18-24 Female	5,535
OVC_SERV_DSD	By: Age/sex: 25+ Female	49,641
OVC_SERV_DSD	Sum of Age/Sex disaggregates	122,263
OVC_SERV_DSD	Age/Sex: <1	7,796
OVC_SERV_DSD	Age/Sex: 1-9	144,131
OVC_SERV_DSD	Program Completion: Active	339,606
OVC_SERV_DSD	Program Completion: Graduation	10,188
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	274,195
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	349,794
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	2,357
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	24
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,217

TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	38
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,098
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	10,138
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	8,116
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	2,022
PMTCT_EID_DSD	Sum of Infant Age disaggregates	10,138
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	285,265
TX_CURR_DSD	Age/Sex: 15-19 Male	1,547
TX_CURR_DSD	Age/Sex: 15-19 Female	3,096
TX_CURR_DSD	Sum of age/sex disaggregates	4,643
TX_CURR_DSD	Age/Sex: <1	155
TX_CURR_DSD	Age/Sex: <1-9	10,914
TX_CURR_DSD	Age/Sex: 10-14 Male	3,008
TX_CURR_DSD	Age/Sex: 10-14 Female	2,934
TX_CURR_DSD	Age/Sex: 20-24 Male	1,957
TX_CURR_DSD	Age/Sex: 50+ Male	18,581
TX_CURR_DSD	Age/Sex: 20-24 Female	12,494
TX_CURR_DSD	Age/Sex: 50+ Female	29,554
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	24,479
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	7,296
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	37,976



TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	7,823
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	39,447
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	11,055
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	49,564
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	23,535
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	39,504
TX_NEW_DSD	By Age/Sex: <1	324
TX_NEW_DSD	By Age/Sex: 1-9	1,624
TX_NEW_DSD	By Age/Sex: 10-14 Male	326
TX_NEW_DSD	By Age/Sex: 15-19 Male	197
TX_NEW_DSD	By Age/Sex: 20-24 Male	2,110
TX_NEW_DSD	By Age/Sex: 50+ Male	1,551
TX_NEW_DSD	By Age/Sex: 10-14 Female	425
TX_NEW_DSD	By Age/Sex: 15-19 Female	778
TX_NEW_DSD	By Age/Sex: 20-24 Female	5,500
TX_NEW_DSD	By Age/Sex: 50+ Female	2,045
TX_NEW_DSD	Sum of Age/Sex disaggregates	12,932
TX_NEW_DSD	Pregnancy status	1,507
TX_NEW_DSD	Breastfeeding status	174
TX_NEW_DSD	FSW	897
TX_NEW_DSD	MSM	264
TX_NEW_DSD	By Key populations: People who inject drugs (PWID)	36
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	4,773
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	1,966
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34,	3,042



	Female, Positive	
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	1,235
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	3,791
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	1,547
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	5,908
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	2,427
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	288,357
TX_PVLS_DSD	Denominator: Indication: Routine	287,704
TX_PVLS_DSD	Denominator: Indication: Targeted	558
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	32
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	42
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	22
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	462
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	7,300
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	86,209
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	5,647
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	188,547
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	37,925



TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	42,139
TX_RET_DSD	Numerator by Status: Pregnant	1,514
TX_RET_DSD	Numerator by Status: Breastfeeding	177
TX_RET_DSD	Denominator by Status: Pregnant	1,678
TX_RET_DSD	Denominator by Status: Breastfeeding	195
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,306
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	9,617
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,263
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	25,725
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,445
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	10,963
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,407



TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	28,305
HTS_SELF_DSD	HTS_SELF_N_DSD	962
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Directly-Assisted	3
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Unassisted	3
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Directly-Assisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Unassisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	56
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	56
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	17
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	17
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	57
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	57



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	25
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	25
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	56
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	56
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	10
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	10
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	49
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	49
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	13
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	13
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	62
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	62
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	33
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	33
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	29
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	29
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	20



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	20
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	481
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	481
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	45
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	97
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	97
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	3
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Unassisted	3
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest PWID, Directly-Assisted	11
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest PWID, Unassisted	11
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	162,615
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	180,682
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	1,820
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	2,452
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	124,908
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	51,532
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	2,636



TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	2,372
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	107,802
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	49,833
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	171,660
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	9,031
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	154,489
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	8,140
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	291,433
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	9,577
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	8,220
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Female	198,757
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Male	74,902
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	232,745
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	232,745
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	140,942
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	38,835
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	93,964
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	17,734

Implementing Mechanism Details

Mechanism ID: 18644	Mechanism Name: EQUIP
Funding Agency: USAID	Procurement Type: Cooperative Agreement



Prime Partner Name: Kheth'Impilo	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	
Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18644 Mechanism Name: EQUIP Prime Partner Name: Kheth'Impilo		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount



Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18645	Mechanism Name: Quality Improvement Capacity for Impact Project (QICIP)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Health Research Inc./New York State Department of Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID:	18645	
Mechanism Name:	Quality Improvement Capacity for Impact Project (QICIP)	
Prime Partner Name:	Health Research Inc./New York State Department of Health	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18647	Mechanism Name: Health Policy Plus (HP+)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Palladium Group	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No



Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18647 Mechanism Name: Health Policy Plus (HP+) Prime Partner Name: Palladium Group		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount



Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18648	Mechanism Name: Maternal and Child Survival Program (MCSP)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18648



Mechanism Name: Maternal and Child Survival Program (MCSP) Prime Partner Name: JHPIEGO		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18655	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18656	TBD: Yes
---------------------	----------



REDACTED

Implementing Mechanism Details

Mechanism ID: 18657	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18661	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18662	Mechanism Name: Youth Power Action
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	
Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID:	18662	
Mechanism Name:	Youth Power Action	
Prime Partner Name:	FHI 360	
Strategic Area	Budget Code	Planned Amount
Care	HKID	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18663	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18664	Mechanism Name: ASM_1116
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: American Society for Microbiology	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)



(No data provided.)

Budget Code Information

Mechanism ID: 18664 Mechanism Name: ASM_1116 Prime Partner Name: American Society for Microbiology		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details



Mechanism ID: 18675	Mechanism Name: ACTION to Control HIV Epidemic through Evidence (ACHIEVE) 2099
Funding Agency: HHS/CDC	Procurement Type: Contract
Prime Partner Name: Institute of Human Virology, Nigeria	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 18,792,118	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 18,792,118	
Funding Source	Funding Amount
GHP-State	18,792,118

Cross-Cutting Budget Attribution(s)

Gender: GBV	1,035,533
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Education	4,032
Food and Nutrition: Policy, Tools, and Service Delivery	31,132
Food and Nutrition: Commodities	50,401
Water	84,808
Economic Strengthening	61,907
Human Resources for Health	7,469,191

**Budget Code Information**

Mechanism ID:	18675	
Mechanism Name:	ACTION to Control HIV Epidemic through Evidence	
Prime Partner Name:	(ACHIEVE)_2099	
	Institute of Human Virology, Nigeria	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	659,728
Strategic Area	Budget Code	Planned Amount
Care	HKID	8,686,083
Strategic Area	Budget Code	Planned Amount
Care	HVTB	97,376
Strategic Area	Budget Code	Planned Amount
Care	PDCS	159,455
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	948,509
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	1,323,583
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	2,137,192
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	342,686
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	4,340,130
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	97,376

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received	5,199



	ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	205,187
PMTCT_ART_DSD	New on ART	1,466
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	3,733
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	205,187
PMTCT_STAT_DSD	Number of new ANC and L&D clients	216,262
PMTCT_STAT_DSD	By Age (Denominator): 10-14	445
PMTCT_STAT_DSD	By Age (Denominator): <15-19	8,079
PMTCT_STAT_DSD	By Age (Denominator): 20-24	36,904
PMTCT_STAT_DSD	By Age (Denominator): 50+	986
PMTCT_STAT_DSD	By Number of known positives: 15-19	83
PMTCT_STAT_DSD	By Number of known positives: 20-24	591
PMTCT_STAT_DSD	By Number of new positives: 15-19	19
PMTCT_STAT_DSD	By Number of new positives: 20-24	224
PMTCT_STAT_DSD	By Number of new negative: 10-14	393
PMTCT_STAT_DSD	By Number of new negative: 15-19	7,523
PMTCT_STAT_DSD	By Number of new negative: 20-24	34,224
PMTCT_STAT_DSD	By Number of new negative: 50+	913
PMTCT_STAT_DSD	By Age (Numerator): 10-14	423
PMTCT_STAT_DSD	By Age (Numerator): 15-19	7,674
PMTCT_STAT_DSD	By Age (Numerator): 20-24	35,058
PMTCT_STAT_DSD	By Age (Numerator): 50+	930
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	84,545
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	57,466
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	22,982
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	4,855
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	1,580

PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	78,089
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	631
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	1,058
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	53,071
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	436
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	417
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	21,245
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	164
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	74
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	4,488
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	31
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	80,301
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	54,587
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	21,843
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	4,611
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	93,186
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on	10,263



	evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	81,804
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,119
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	862,073
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	754
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	788
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	1,728
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	1,310
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	2,872
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	97
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	1,775



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	986
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	25
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	1,046
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	4,000
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	18
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	2,743
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	74
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	1,954
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	29
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	8,876
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	762
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	5,070
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	223
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	588
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	18
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	694



HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	20,475
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	104
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	19,644
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	80
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	14,954
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	153
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	9,880
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	118
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	31,867
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	591
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	15,392
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	302
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	5,386
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	106
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	2,632
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	73



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	34,563
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	307
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	3,730
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	32
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	156
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	187
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	183
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	214
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	225
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	243
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	31



HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	288
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	283
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	25
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	10
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	161
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	144
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	329
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	158
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	74
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	52
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	176
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	79



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	53
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	15
HTC_TST_DSD	By Key Population: FSW, Negative	29,812
HTC_TST_DSD	By Key Population: FSW, Positive	2,375
HTC_TST_DSD	By Key Population: MSM, Negative	6,184
HTC_TST_DSD	By Key Population: MSM, Positive	563
HTC_TST_DSD	By Key Population: PWID, Negative	3,233
HTC_TST_DSD	By Key Population: PWID, Positive	176
HTC_TST_DSD	By Key Population: TG, Negative	289
HTC_TST_DSD	By Key Population: TG, Positive	37
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	4
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	26
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	18
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	11
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	65
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	117
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	22
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	12
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	349
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	7,066



HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	26
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	39,443
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	354
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	25
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	13,753
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	99
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	13,345
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	94
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	12,286
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	113
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	8,737
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	85
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	21,381
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	823
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	14,895
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	368
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	9,720
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	262
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male,	7,965



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	142
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	15,831
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	212
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Female, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Male, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Negative	13
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Male, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 1-9, Unknown Sex, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 1-9, Unknown Sex, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Negative	10
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Negative	34
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Negative	13
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Negative	36
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Negative	16
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Negative	29
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Negative	23
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male,	36



	Negative	
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Negative	23
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Negative	29
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Negative	19
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Negative	36
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	350
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	243
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	234
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	161
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	350
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	147
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	710
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	67
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	584
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	243
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	871



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	174
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	410
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	147
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	479
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	114
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	2,324
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	72
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	2,090
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	1,756
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	38
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	1,296
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	1,615
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	103
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	1,410
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	46
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	1,835
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	50



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	1,578
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	87
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	8,381
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	1,318
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	5,515
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	271
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	3,335
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	430
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	2,455
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	83
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	2,034
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	232
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	794
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	37
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	1,628
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	44
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49,	775



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	34
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	166
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	11
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	55
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	28
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	27
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49,	5



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	54,318
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	753
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	22,458
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	572
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	34,200
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	693
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	18,244
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	314
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	26,256
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	598
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	13,274
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	606
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	22,435
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	951
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	11,308
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	579
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29,	77,252



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	913
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	51,334
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	143
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	19,370
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	109
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	4,205
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	224
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	194
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	217
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	22
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	206
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	184
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	33
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39,	248



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	232
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	393
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	20,186
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	1,036
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	8,537
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	173
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	12,637
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	601
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	10,133
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	412
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	9,333
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	525
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	5,976
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	284



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	7,416
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	653
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	5,373
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	438
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	5,004
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	5,004
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	210
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,786
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	213
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,800
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	210
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2,786
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	213

TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,800
GEND_GBV_DSD	Number of people receiving post-GBV care	3,260
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	2,159
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	1,082
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	983
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	30
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	40
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	8
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	18
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	46
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	74
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	24
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	23
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	80
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	106
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	37
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	13
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	391
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	586
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	96
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	75
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	3
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	3
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	574
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	84
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	141



GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	231
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	32
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	55
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	173
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	22
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	39
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	173
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	22
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	39
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	283,741
OVC_SERV_DSD	Age/Sex: 10-14 Male	32,872
OVC_SERV_DSD	Age/Sex: 15-17 Male	14,822
OVC_SERV_DSD	By: Age/sex: Male 18-24	4,815
OVC_SERV_DSD	By: Age/sex: Male 25+	5,846
OVC_SERV_DSD	Age/Sex: 10-14 Female	31,816
OVC_SERV_DSD	Age/Sex: 15-17 Female	15,164
OVC_SERV_DSD	By: Age/sex: 18-24 Female	4,424
OVC_SERV_DSD	By: Age/sex: 25+ Female	58,218
OVC_SERV_DSD	Sum of Age/Sex disaggregates	94,674
OVC_SERV_DSD	Age/Sex: <1	5,600
OVC_SERV_DSD	Age/Sex: 1-9	110,156
OVC_SERV_DSD	Program Completion: Active	275,477



OVC_SERV_DSD	Program Completion: Graduation	8,264
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	210,435
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	283,741
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,454
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	10
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	628
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	28
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	794
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	4,934
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	3,954
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	980
PMTCT_EID_DSD	Sum of Infant Age disaggregates	4,934
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	125,421



TX_CURR_DSD	Age/Sex: 15-19 Male	663
TX_CURR_DSD	Age/Sex: 15-19 Female	1,292
TX_CURR_DSD	Sum of age/sex disaggregates	1,955
TX_CURR_DSD	Age/Sex: <1	37
TX_CURR_DSD	Age/Sex: <1-9	3,315
TX_CURR_DSD	Age/Sex: 10-14 Male	1,132
TX_CURR_DSD	Age/Sex: 10-14 Female	1,059
TX_CURR_DSD	Age/Sex: 20-24 Male	914
TX_CURR_DSD	Age/Sex: 50+ Male	8,564
TX_CURR_DSD	Age/Sex: 20-24 Female	5,870
TX_CURR_DSD	Age/Sex: 50+ Female	7,566
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	11,203
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	3,791
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	17,367
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	4,063
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	18,041
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	5,752
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	22,663
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	12,235
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	18,861
TX_NEW_DSD	By Age/Sex: <1	85
TX_NEW_DSD	By Age/Sex: 1-9	622
TX_NEW_DSD	By Age/Sex: 10-14 Male	135
TX_NEW_DSD	By Age/Sex: 15-19 Male	73



TX_NEW_DSD	By Age/Sex: 20-24 Male	390
TX_NEW_DSD	By Age/Sex: 50+ Male	602
TX_NEW_DSD	By Age/Sex: 10-14 Female	199
TX_NEW_DSD	By Age/Sex: 15-19 Female	374
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,854
TX_NEW_DSD	By Age/Sex: 50+ Female	497
TX_NEW_DSD	Sum of Age/Sex disaggregates	4,124
TX_NEW_DSD	Pregnancy status	1,249
TX_NEW_DSD	Breastfeeding status	71
TX_NEW_DSD	FSW	1,651
TX_NEW_DSD	MSM	328
TX_NEW_DSD	TG	13
TX_NEW_DSD	By Key populations: People who inject drugs (PWID)	121
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	2,581
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	1,225
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	1,674
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	766
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	2,057
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	972
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	3,180
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	1,516
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	123,269
TX_PVLS_DSD	Denominator: Indication: Routine	123,266

TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	2,040
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	34,833
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	2,098
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	84,302
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	17,980
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	19,980
TX_RET_DSD	Numerator by Status: Pregnant	1,224
TX_RET_DSD	Numerator by Status: Breastfeeding	81
TX_RET_DSD	Denominator by Status: Pregnant	1,360
TX_RET_DSD	Denominator by Status: Breastfeeding	93
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	497
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,964
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	471
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	12,015
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	559



	stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,721
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	529
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	13,148
HTS_SELF_DSD	HTS_SELF_N_DSD	212
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	9
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	9
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	11
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	11
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	11



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	11
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	10
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	10
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	12
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	12
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	9
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	9
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	3
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	3
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	106
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	106
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	9

HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	22
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	22
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Unassisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest PWID, Directly-Assisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest PWID, Unassisted	5
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	73,174
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	81,298
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	2,022
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	1,791
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	52,350
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	25,154
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	1,654
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	1,358
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	47,285
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	22,882
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	77,236
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT,	4,078

	Life-long ART, New, Positive	
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	69,525
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	3,664
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	125,425
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	2,392
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	2,439
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	82,289
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	38,355
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	100,337
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	100,337
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	65,745
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	12,079
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	43,841
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	3,811

Implementing Mechanism Details

Mechanism ID: 18676	Mechanism Name: Global Action towards HIV Epidemic Control in Subnational units in Nigeria (4GATES PROJECT)_2100
Funding Agency: HHS/CDC	Procurement Type: Contract
Prime Partner Name: Catholic Caritas Foundation of Nigeria (CCFN)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	



G2G: No	Managing Agency:
Total All Funding Sources: 5,806,210	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 5,806,210	
Funding Source	Funding Amount
GHP-State	5,806,210

Cross-Cutting Budget Attribution(s)

Gender: GBV	50,504
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Gender: Gender Equality	14,479
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Monitoring and Evaluation
Sub Area:	Capacity building
Sub Area:	Implementation
Sub Area:	Collection and Use of Gender-related Strategic Information
Economic Strengthening	25,383
Water	18,099
Human Resources for Health	349,900
Food and Nutrition: Commodities	18,099



Budget Code Information

Mechanism ID:	18676	
Mechanism Name:	Global Action towards HIV Epidemic Control in Subnational	
Prime Partner Name:	units in Nigeria (4GATES PROJECT)_2100	
	Catholic Caritas Foundation of Nigeria (CCFN)	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	757,344
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	199,711
Strategic Area	Budget Code	Planned Amount
Care	PDCS	439,366
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	751,765
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	1,061,775
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	2,476,421
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	119,828

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	3,061
PMTCT_ART_DSD	Number of pregnant women with known HIV status	159,192

	(includes women who were tested for HIV and received their results)	
PMTCT_ART_DSD	New on ART	1,145
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,916
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	159,192
PMTCT_STAT_DSD	Number of new ANC and L&D clients	167,971
PMTCT_STAT_DSD	By Age (Denominator): 10-14	301
PMTCT_STAT_DSD	By Age (Denominator): <15-19	5,037
PMTCT_STAT_DSD	By Age (Denominator): 20-24	31,936
PMTCT_STAT_DSD	By Age (Denominator): 50+	800
PMTCT_STAT_DSD	By Number of known positives: 15-19	68
PMTCT_STAT_DSD	By Number of known positives: 20-24	363
PMTCT_STAT_DSD	By Number of known positives: 50+	1
PMTCT_STAT_DSD	By Number of new positives: 15-19	42
PMTCT_STAT_DSD	By Number of new positives: 20-24	241
PMTCT_STAT_DSD	By Number of new negative: 10-14	277
PMTCT_STAT_DSD	By Number of new negative: 15-19	4,686
PMTCT_STAT_DSD	By Number of new negative: 20-24	29,731
PMTCT_STAT_DSD	By Number of new negative: 50+	744
PMTCT_STAT_DSD	By Age (Numerator): 10-14	287
PMTCT_STAT_DSD	By Age (Numerator): 15-19	4,782
PMTCT_STAT_DSD	By Age (Numerator): 20-24	30,330
PMTCT_STAT_DSD	By Age (Numerator): 50+	757
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	64,644
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	43,947
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	17,582
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	3,724
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	759
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult	60,165



	25-29, Female, Newly Identified Negative	
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	491
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	511
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	40,900
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	328
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	201
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	16,363
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	138
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	32
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	3,469
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	13
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	61,417
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	41,748
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	16,701
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	3,535
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	349,820
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	328
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	335



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	287
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	165
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	813
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	38
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	272
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	544
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	35
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	445
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	25
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	1,488
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	41
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	3,944
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	52
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	4,857



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	37
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	2,960
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	42
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	1,719
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	39
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	7,914
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	402
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	3,611
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	112
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	610
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	597
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	20
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	7,315
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	122



HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	909
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	168
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	143
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	110
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	175
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	136
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	151
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	192
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	186
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female,	101



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	51
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	170
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	212
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	46
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	101
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	205
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	21
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	5,458
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	30,562
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	294
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	25
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	2,743
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	104
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	2,871
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	66
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	4,558
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	91



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	2,700
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	45
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	7,323
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	356
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	4,866
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	99
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	4,762
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	238
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	3,100
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	179
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	2,306
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	79
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	56
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	82
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	47
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	43
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	56
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	49



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	144
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	93
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	82
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	177
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	59
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	64
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	49
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	98
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	36
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	821
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	57
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	655
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	621
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	37
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	406
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	571



HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	78
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	444
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	36
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	646
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	37
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	499
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	66
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	20,126
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	513
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	9,111
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	281
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	10,980
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	513
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	7,409
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	140
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	8,754
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	386



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	5,354
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	282
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	7,315
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	642
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	4,494
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	356
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	59,691
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	767
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	39,665
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	84
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	14,966
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	81
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	3,244
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	182
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	103
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	13



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	167
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	103
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	105
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	138
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	168
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	193
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	6,412
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	631
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	4,509
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	114
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	4,280



HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	391
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	3,168
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	146
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	3,029
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	350
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	2,931
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	235
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	2,058
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	473
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	2,822
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	413
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,823
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	2,823
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	59
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,570
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with	44

	documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,155
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	59
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,570
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	44
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,155
GEND_GBV_DSD	Number of people receiving post-GBV care	1,620
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	1,157
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	465
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	415
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	6
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	42
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	9
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	9
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	8
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	68
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	22
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	16
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	45
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	42
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	16

GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	14
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	83
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	77
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	65
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	8
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	3
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	15
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	6
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	175
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	58
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	270
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	26
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	69
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	22
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	106
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	8
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	51
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	18
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	78
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	7
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	51

GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	18
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	78
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	7
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	596
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	6
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	292
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	5
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	297
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	2,899
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	2,319
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	580
PMTCT_EID_DSD	Sum of Infant Age disaggregates	2,899
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	61,621
TX_CURR_DSD	Age/Sex: 15-19 Male	335



TX_CURR_DSD	Age/Sex: 15-19 Female	464
TX_CURR_DSD	Sum of age/sex disaggregates	799
TX_CURR_DSD	Age/Sex: <1	28
TX_CURR_DSD	Age/Sex: <1-9	2,072
TX_CURR_DSD	Age/Sex: 10-14 Male	600
TX_CURR_DSD	Age/Sex: 10-14 Female	560
TX_CURR_DSD	Age/Sex: 20-24 Male	507
TX_CURR_DSD	Age/Sex: 50+ Male	5,150
TX_CURR_DSD	Age/Sex: 20-24 Female	1,459
TX_CURR_DSD	Age/Sex: 50+ Female	6,535
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	5,375
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	1,567
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	8,343
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	1,682
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	8,668
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	2,379
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	10,887
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	5,062
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	9,522
TX_NEW_DSD	By Age/Sex: <1	55
TX_NEW_DSD	By Age/Sex: 1-9	369
TX_NEW_DSD	By Age/Sex: 10-14 Male	73
TX_NEW_DSD	By Age/Sex: 15-19 Male	74
TX_NEW_DSD	By Age/Sex: 20-24 Male	178

TX_NEW_DSD	By Age/Sex: 50+ Male	614
TX_NEW_DSD	By Age/Sex: 10-14 Female	80
TX_NEW_DSD	By Age/Sex: 15-19 Female	140
TX_NEW_DSD	By Age/Sex: 20-24 Female	529
TX_NEW_DSD	By Age/Sex: 50+ Female	887
TX_NEW_DSD	Sum of Age/Sex disaggregates	2,575
TX_NEW_DSD	Pregnancy status	644
TX_NEW_DSD	Breastfeeding status	45
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	1,234
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	562
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	799
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	356
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	976
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	447
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	1,514
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	694
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	60,445
TX_PVLS_DSD	Denominator: Indication: Routine	60,204
TX_PVLS_DSD	Denominator: Indication: Targeted	242
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	44
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	198



TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1,392
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	16,835
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	1,448
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	40,529
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	8,715
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	9,678
TX_RET_DSD	Numerator by Status: Pregnant	619
TX_RET_DSD	Numerator by Status: Breastfeeding	46
TX_RET_DSD	Denominator by Status: Pregnant	687
TX_RET_DSD	Denominator by Status: Breastfeeding	51
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	265
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,521
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	251
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,673
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	302



	stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,810
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	277
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,292
HTS_SELF_DSD	HTS_SELF_N_DSD	294
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	7
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	7
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	18
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	18
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	10
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	10
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	18



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	18
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	17
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	17
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	20
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	20
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	12
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	12
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	14
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	14
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	9
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	9
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	147
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	147
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	15

HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	28
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	28
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	35,844
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	39,825
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	249
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	198
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	26,004
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	13,378
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	359
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	253
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	23,646
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	11,591
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	37,836
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	1,998
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	34,050
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	1,799
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	61,621
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	1,666



TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	1,561
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	41,819
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	16,585
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	49,296
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	49,296
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	25,360
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	14,328
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	16,909
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	5,032

Implementing Mechanism Details

Mechanism ID: 18677	Mechanism Name: Partnering Effectively to end AIDS through Results and Learning (PEARL)_2097
Funding Agency: HHS/CDC	Procurement Type: Contract
Prime Partner Name: Center for Integrated Health Programs	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 5,881,634	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 5,881,634	
Funding Source	Funding Amount
GHP-State	5,881,634



Cross-Cutting Budget Attribution(s)

Gender: GBV	73,211
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Food and Nutrition: Commodities	23,877
Water	10,672
Economic Strengthening	55,586
Education	200,369
Human Resources for Health	70,597

Budget Code Information

Mechanism ID:	18677	
Mechanism Name:	Partnering Effectively to end AIDS through Results and Learning (PEARL)_2097	
Prime Partner Name:	Center for Integrated Health Programs	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	799,492
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	209,871
Strategic Area	Budget Code	Planned Amount



Care	PDCS	253,166
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	811,868
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	619,601



Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	3,061,052
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	126,584

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	4,040
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	204,952
PMTCT_ART_DSD	New on ART	1,500
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	2,540
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	204,952
PMTCT_STAT_DSD	Number of new ANC and L&D clients	216,220
PMTCT_STAT_DSD	By Age (Denominator): 10-14	460
PMTCT_STAT_DSD	By Age (Denominator): <15-19	9,441
PMTCT_STAT_DSD	By Age (Denominator): 20-24	44,782
PMTCT_STAT_DSD	By Age (Denominator): 50+	1,335
PMTCT_STAT_DSD	By Number of known positives: 15-19	139
PMTCT_STAT_DSD	By Number of known positives: 20-24	618
PMTCT_STAT_DSD	By Number of known positives: 50+	7

PMTCT_STAT_DSD	By Number of new positives: 10-14	1
PMTCT_STAT_DSD	By Number of new positives: 15-19	60
PMTCT_STAT_DSD	By Number of new positives: 20-24	299
PMTCT_STAT_DSD	By Number of new positives: 50+	3
PMTCT_STAT_DSD	By Number of new negative: 10-14	427
PMTCT_STAT_DSD	By Number of new negative: 15-19	8,731
PMTCT_STAT_DSD	By Number of new negative: 20-24	41,620
PMTCT_STAT_DSD	By Number of new negative: 50+	1,238
PMTCT_STAT_DSD	By Age (Numerator): 10-14	439
PMTCT_STAT_DSD	By Age (Numerator): 15-19	8,972
PMTCT_STAT_DSD	By Age (Numerator): 20-24	42,547
PMTCT_STAT_DSD	By Age (Numerator): 50+	1,274
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	79,745
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	54,198
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	21,677
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	4,582
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	1,036
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	74,231
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	486
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	696
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	50,450
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	332
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	281
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	20,184
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult	138



	35-39, Female, Newly Identified Positive	
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	47
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	4,267
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	26
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	75,752
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	51,496
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	20,601
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	4,354
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	575,746
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	163
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	164
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	868
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	633
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	1,565
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	32
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	981



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	824
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	840
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	351
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	507
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	571
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	4,247
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	42
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	2,169
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	7,217
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	104
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	3,920



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	1,093
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	1,110
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	25
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	1,802
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	263
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	266
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	187
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	246
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	197
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	225



HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	325
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	268
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	32
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	121
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	153
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	28
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	126
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	149
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	136
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	203
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	45
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	7,146
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	55
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	39,950
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	590



HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	34
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	8,550
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	95
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	7,407
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	86
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	29,125
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	516
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	13,956
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	397
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	41,378
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	1,129
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	24,964
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	542
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	17,001
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	525
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	19,951
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	417



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	3,479
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	64
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	126
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	89
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	79
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	52
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	126
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	50
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	236
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	210
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	89
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	287
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	52
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	145
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	50
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	156
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	34



HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	1,209
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	40
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	1,096
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	911
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	26
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	677
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	845
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	54
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	738
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	29
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	950
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	828
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	64
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	5,895
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	139
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	3,643



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	90
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	3,572
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	139
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	2,956
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	44
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	2,814
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	107
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	2,152
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	90
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	2,826
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	176
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	1,838
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	113
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	78,055
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	546
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	51,854
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	103



HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	19,566
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	78
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	4,239
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	224
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	145
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	214
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	167
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	173
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	229
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	217
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	24



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	295
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	30,041
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	1,099
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	18,400
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	238
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	20,069
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	749
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	12,934
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	287
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	14,191
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	667
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	11,946
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	442
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	9,648
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	881
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	11,507

HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	763
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	4,484
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	4,484
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	63
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,501
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	69
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,856
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	63
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2,501
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	69
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,856
GEND_GBV_DSD	Number of people receiving post-GBV care	5,572
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	4,106
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	1,457

GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	1,312
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	998
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	190
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	186
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	19
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	671
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	151
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	273
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	26
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	890
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	194
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	88
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	23
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	459
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	161
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	178
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	17
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	120
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	216
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	61
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	121
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	46
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	86
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	22

GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	49
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	35
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	63
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	21
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	40
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	35
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	63
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	21
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	40
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,081
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	5
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	558
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with	522



	documented HIV-positive status who are on ART during TB treatment during the reporting period)	
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	3,828
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	3,064
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	764
PMTCT_EID_DSD	Sum of Infant Age disaggregates	3,828
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	97,961
TX_CURR_DSD	Age/Sex: 15-19 Male	524
TX_CURR_DSD	Age/Sex: 15-19 Female	976
TX_CURR_DSD	Sum of age/sex disaggregates	1,500
TX_CURR_DSD	Age/Sex: <1	22
TX_CURR_DSD	Age/Sex: <1-9	1,623
TX_CURR_DSD	Age/Sex: 10-14 Male	509
TX_CURR_DSD	Age/Sex: 10-14 Female	527
TX_CURR_DSD	Age/Sex: 20-24 Male	630
TX_CURR_DSD	Age/Sex: 50+ Male	6,958
TX_CURR_DSD	Age/Sex: 20-24 Female	3,845
TX_CURR_DSD	Age/Sex: 50+ Female	7,699
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	8,896
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	2,885
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	13,799
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	3,096
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	14,331
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male,	4,376



	Positive	
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	18,012
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	9,312
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	11,924
TX_NEW_DSD	By Age/Sex: <1	26
TX_NEW_DSD	By Age/Sex: 1-9	196
TX_NEW_DSD	By Age/Sex: 10-14 Male	56
TX_NEW_DSD	By Age/Sex: 15-19 Male	42
TX_NEW_DSD	By Age/Sex: 20-24 Male	1,736
TX_NEW_DSD	By Age/Sex: 50+ Male	373
TX_NEW_DSD	By Age/Sex: 10-14 Female	92
TX_NEW_DSD	By Age/Sex: 15-19 Female	188
TX_NEW_DSD	By Age/Sex: 20-24 Female	4,183
TX_NEW_DSD	By Age/Sex: 50+ Female	283
TX_NEW_DSD	Sum of Age/Sex disaggregates	6,953
TX_NEW_DSD	Pregnancy status	347
TX_NEW_DSD	Breastfeeding status	14
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	878
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	424
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	586
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	266
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	706
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	332
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	1,073

	Female, Positive	
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	523
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	97,522
TX_PVLS_DSD	Denominator: Indication: Routine	96,067
TX_PVLS_DSD	Denominator: Indication: Targeted	1,352
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	19
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	255
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	22
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	1,056
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1,791
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	26,507
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	1,818
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	65,951
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	10,964
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	12,184
TX_RET_DSD	Numerator by Status: Pregnant	252
TX_RET_DSD	Numerator by Status: Breastfeeding	12
TX_RET_DSD	Denominator by Status: Pregnant	278
TX_RET_DSD	Denominator by Status: Breastfeeding	14



TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	330
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,019
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	332
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7,279
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	367
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,576
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	364
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7,868
HTS_SELF_DSD	HTS_SELF_N_DSD	126
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	1



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	18
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	18
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	3
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	3



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	63
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	63
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	4
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	9
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	9
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	57,429
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	63,809
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	230
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	64
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	45,243
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	18,277
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	747
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	232
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	39,123



TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	17,337
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	60,614
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	3,195
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	54,553
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	2,878
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	97,961
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	2,679
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	1,971
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	64,977
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	28,347
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	78,369
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	78,369
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	41,662
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	23,587
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	27,781
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	4,942

Implementing Mechanism Details

Mechanism ID: 70254	Mechanism Name: [Placeholder - 70254 Nigeria DOD]
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: [Placeholder]	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 70254		
Mechanism Name: [Placeholder - 70254 Nigeria DOD]		
Prime Partner Name: [Placeholder]		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70255	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70256	Mechanism Name: [Placeholder - 70256 Nigeria HHS/CDC]
Funding Agency: HHS/CDC	Procurement Type: Contract
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)



(No data provided.)

Budget Code Information

Mechanism ID: 70256 Mechanism Name: [Placeholder - 70256 Nigeria HHS/CDC] Prime Partner Name: [Placeholder]		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details



Mechanism ID: 70257	Mechanism Name: [Placeholder - 70257 Nigeria HHS/CDC]
Funding Agency: HHS/CDC	Procurement Type: Contract
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 70257 Mechanism Name: [Placeholder - 70257 Nigeria HHS/CDC] Prime Partner Name: [Placeholder]		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0



Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount



Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70258	Mechanism Name: [Placeholder - 70258 Nigeria HHS/CDC]
Funding Agency: HHS/CDC	Procurement Type: Contract
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 70258 Mechanism Name: [Placeholder - 70258 Nigeria HHS/CDC] Prime Partner Name: [Placeholder]		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70259	Mechanism Name: [Placeholder - 70259 Nigeria HHS/CDC]
Funding Agency: HHS/CDC	Procurement Type: Contract



Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 70259 Mechanism Name: [Placeholder - 70259 Nigeria HHS/CDC] Prime Partner Name: [Placeholder]		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount



Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70260	Mechanism Name: [Placeholder - 70260 Nigeria HHS/CDC]
Funding Agency: HHS/CDC	Procurement Type: Contract
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 70260 Mechanism Name: [Placeholder - 70260 Nigeria HHS/CDC] Prime Partner Name: [Placeholder]		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70261	Mechanism Name: [Placeholder - 70261 Nigeria HHS/CDC]
Funding Agency: HHS/CDC	Procurement Type: Contract
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted

Approved



TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	
Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	70261	
Mechanism Name:	[Placeholder - 70261 Nigeria HHS/CDC]	
Prime Partner Name:	[Placeholder]	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70262	Mechanism Name: [Placeholder - 70262 Nigeria HHS/CDC]
Funding Agency: HHS/CDC	Procurement Type: Contract
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information



Mechanism ID: 70262 Mechanism Name: [Placeholder - 70262 Nigeria HHS/CDC] Prime Partner Name: [Placeholder]		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70263	Mechanism Name: [Placeholder - 70263 Nigeria HHS/CDC]
Funding Agency: HHS/CDC	Procurement Type: Contract
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes



Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 70263 Mechanism Name: [Placeholder - 70263 Nigeria HHS/CDC] Prime Partner Name: [Placeholder]		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount



Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70264	Mechanism Name: [Placeholder - 70264 Nigeria HHS/HRSA]
Funding Agency: HHS/CDC	Procurement Type: Contract
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 70264



Mechanism Name: [Placeholder - 70264 Nigeria HHS/HRSA] Prime Partner Name: [Placeholder]		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70265	Mechanism Name: [Placeholder - 70265 Nigeria HHS/HRSA]
Funding Agency: HHS/CDC	Procurement Type: Contract
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	

Approved



G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	70265	
Mechanism Name:	[Placeholder - 70265 Nigeria HHS/HRSA]	
Prime Partner Name:	[Placeholder]	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0



Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70266	Mechanism Name: [Placeholder - 70266 Nigeria HHS/HRSA]
Funding Agency: HHS/CDC	Procurement Type: Contract
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	70266
Mechanism Name:	[Placeholder - 70266 Nigeria HHS/HRSA]
Prime Partner Name:	[Placeholder]



Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70267	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70268	TBD: Yes
REDACTED	

**Implementing Mechanism Details**

Mechanism ID: 70269	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70270	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70271	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70272	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70273	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70274	TBD: Yes
REDACTED	

Implementing Mechanism Details

Approved



Mechanism ID: 70275	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70276	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70512	TBD: Yes
REDACTED	



Agency Information - Costs of Doing Business

U.S. Agency for International Development

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Computers/IT Services		388,491		388,491	0	388,491
ICASS		1,963,480		1,963,480	0	1,963,480
Institutional Contractors		4,027,074		4,027,074	0	4,027,074
Management Meetings/Professional Development		200,432		200,432	0	200,432
Non-ICASS Administrative Costs		261,109		261,109	0	261,109
Staff Program Travel		788,447		788,447	0	788,447
USG Staff Salaries and Benefits - Internationally Recruited		2,544,372		2,544,372	0	2,544,372
USG Staff Salaries and Benefits - Locally Recruited		2,095,719		2,095,719	0	2,095,719



Total	0	12,269,124	0	12,269,124	0	12,269,124
--------------	----------	-------------------	----------	-------------------	----------	-------------------

U.S. Department of Defense

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Computers/IT Services		282,000		282,000	0	282,000
ICASS		0		0	1,343,495	1,343,495
Management Meetings/Professional Development		228,932		228,932	0	228,932
Non-ICASS Administrative Costs		568,921		568,921	0	568,921
Non-ICASS Motor Vehicles		238,658		238,658	61,342	300,000
Staff Program Travel		397,455		397,455	0	397,455
USG Staff Salaries and Benefits - Internationally Recruited		670,330		670,330	0	670,330
USG Staff Salaries and Benefits - Locally Recruited		913,483		913,483	0	913,483



Total	0	3,299,779	0	3,299,779	1,404,837	4,704,616
--------------	----------	------------------	----------	------------------	------------------	------------------

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Capital Security Cost Sharing		1,881,179		1,881,179	0	1,881,179
Computers/IT Services		545,353		545,353	0	545,353
ICASS	161,883	1,800,843		1,962,726	0	1,962,726
Institutional Contractors	0	605,789	0	605,789	0	605,789
Management Meetings/Professional Development		451,086		451,086	0	451,086
Non-ICASS Administrative Costs		410,624		410,624	0	410,624
Staff Program Travel		947,513		947,513	0	947,513
USG Staff Salaries and Benefits - Internationally Recruited	1,800,617	359,635		2,160,252	0	2,160,252
USG Staff Salaries and		3,714,408		3,714,408	0	3,714,408



Benefits - Locally Recruited						
Total	1,962,500	10,716,430	0	12,678,930	0	12,678,930

U.S. Department of State

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
ICASS		103,094		103,094	0	103,094
Management Meetings/Profes sional Development		0		0	25,000	25,000
Non-ICASS Administrative Costs		0		0	5,000	5,000
Staff Program Travel				0	100,000	100,000
USG Staff Salaries and Benefits - Locally Recruited				0	524,000	524,000
Total	0	103,094	0	103,094	654,000	757,094